Full Study Protocol and Statistical Analysis Plan  
 
  
Study Title:  A Phase 1b/2 Study of Repeat rA diation, Minocycline, and 
Bevacizumab in patients with recurrent gli Oma (RAMBO)  
 
Protocol Version 10: 12/03/[ADDRESS_568643] #: [STUDY_ID_REMOVED]  
Unique Protocol ID: HCI55264  
U of U IRB#: IRB_00055264  
   
Principal Investigator:  [INVESTIGATOR_447134], MD, MS  
Huntsman Cancer Institute  
 
Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
 
A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab 
in patients with recurrent gliOma (RAMBO)  
Trial ID: HCI55264/ IRB# [ADDRESS_568644] of Hope 
     Salt Lake City, UT [ZIP_CODE] 
[PHONE_9341] [EMAIL_8557] 
 Sub-investigator(s)  Howard Colman, MD, PhD Huntsman Cancer Institute 
  2000 Circle of Hope 
  Salt Lake City, UT [ZIP_CODE] 
[PHONE_9342] [EMAIL_7037]  Dennis Shrieve, MD Huntsman Cancer Institute Radiation Oncology 2000 Circle of Hope 
     Salt Lake City, UT [ZIP_CODE] 
[PHONE_9343] [EMAIL_8558]  Sean Strope, PA  Huntsman Cancer Institute 2000 Circle of Hope  Salt Lake City, UT [ZIP_CODE] [PHONE_9341] [EMAIL_8559]  Karen Salzman , MD 
Huntsman Cancer Institute University of Utah School of Medicine Department of Radiology 2000 Circle of Hope 
     Salt Lake City, UT [ZIP_CODE] 
[PHONE_9344] [EMAIL_8560]  
Page 1 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
John Hoffman, MD 
Professor of Radiology and Neurology Director of  Nuclear  Medicine  
University of Utah School of Medicine Director: Molecular Imaging Program  
Huntsman Cancer Institute University of Utah School of Medicine 1950 Circle of Hope Suite 6810 Salt Lake City, UT [ZIP_CODE] Telephone: ([PHONE_9345] Fax: ([PHONE_9346] Email: [EMAIL_8561] 
 Randy Jensen, MD, PhD Huntsman Cancer Institute University of Utah School of Medicine 
Department of Neurosurgery 2000 Circle of Hope 
     Salt Lake City, UT [ZIP_CODE] 
[PHONE_9342] [EMAIL_8562]  Matthew Poppe, MD 1950 Circle of Hope Salt Lake City, UT [ZIP_CODE] [EMAIL_8563] 
 David Gaffney, MD, PhD 2000 Circle of Hope Salt Lake City, UT [ZIP_CODE] 
[EMAIL_8564]  Gita Suneja, MD  
2000 Circle of Hope Salt Lake City, UT [ZIP_CODE] Gita.suneja @hci.utah.edu 
 Angela Gerrard, NP [ADDRESS_568645]@ hci.utah.edu 
 
   
 
Page 2 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
 
Investigational agents  Bevacizumab and Minocycline 
 
 IND Number      Exempt    
  
 
Historical Protocol Versions 
Version 1:  6-20-12 
Version 2: 7-23-2012 
Version 3: 8-24-2012 Version 4: 9-12-2012 Version 5:12-17-2012 Version 6: 2-26-2013 Version 7: 04-04-2013 Version 8: 08-08-2013 Version 9: 09-04-2014 Version 10: 12-03-2015 
 
 
  
Page 3 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
TABLE OF CONTENTS  
             
                           Page  
LIST OF ABBREVIATIONS…………………………………………………………………..6 
PROTOCOL SIGNATURE [CONTACT_1783]……………………………….............................................8 
STUDY SUMMARY   ………………………………………………………………………….....9 
1.0 OBJECTIVES  ..................................................................................................................13  
1.1 Primary Objectives .................................................................................................13  
1.2 Secondary Objectives .............................................................................................13  
2.0 BACKGROUND  ..............................................................................................................13  
2.1 Bevacizumab  ..........................................................................................................16  
2.1.1  Description  ............................................................................................16  
2.1.1  Beva cizumab Safety  ..............................................................................16  
2.2 Minocycline ...........................................................................................................18  
2.2.1  Description  ............................................................................................18  
2.2.2  Clinical Pharmacology  ..........................................................................18  
2.2.3  Adverse Reactions  .................................................................................19  
3.0 RATIONALE  ...................................................................................................................20  
4.0 STUDY DESIGN ..............................................................................................................21  
4.1 Description  .............................................................................................................21  
4.2 Dose Limiting Toxicity  ..........................................................................................21  
4.3 Number of Patients ................................................................................................22  
4.4 Number of Study Centers.......................................................................................22  
4.5 Duration of Patient Participation  ...........................................................................22  
4.6 Duration of Study ...................................................................................................22  
5.0 ELIGIBILITY CRITERIA  .............................................................................................23  
5.1 Inclusion Criteria  ...................................................................................................23  
5.2 Exclusion Criteria  ..................................................................................................24  
5.3 Screen Failures  .......................................................................................................25  
5.4 Prior Treatment  ......................................................................................................25  
6.0 CONCOMITANT TREATMENT .................................................................................26  
7.0 TREATMENT PLAN  ......................................................................................................26  
7.1 Bevacizumab  ..........................................................................................................26  
7.1.1  How Supplied, Stored, Packaged and Labeled .....................................26  
7.1.2  Preparation and Administration ............................................................26  
Page 4 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
7.1.3  Accountability and Compliance ............................................................27  
7.2 Minocycline ...........................................................................................................27  
7.2.1  How Supplied, Stored, Packaged and Labeled .....................................27  
7.2.2  Preparation and Administration ............................................................28  
7.2.3  Accountability and Compliance ............................................................28  
8.0 TOXICITIES AND DOSE MODIFICATION  ..............................................................28  
8.1 Bevacizumab  ..........................................................................................................28  
8.2 Minocycline ...........................................................................................................31  
8.3 Discontinuation of Treatment and Withdrawal of Patients....................................32  
9.0 STUDY CALENDAR  ......................................................................................................33  
10.0  STUDY PROCEDURES  .................................................................................................34  
10.1  Screening Evaluation  .............................................................................................34  
10.2  Baseline Evaluation  ...............................................................................................34  
10.3  Day 1 of subsequent cycles (± 7 Days) ..................................................................34  
10.4  Day 15 of subsequent cycles (± 7 Days)  ................................................................[ADDRESS_568646]- radiation  ...........................................................................36  
10.9  Continuously during trial .......................................................................................36  
11.0  CRITERIA FOR EVALUATION AND ENDPOINT  ..................................................36  
11.1  Efficacy Evaluation  ................................................................................................36  
11.2  Safety Evaluation  ...................................................................................................38  
11.2.1  Physical Examination  ............................................................................38  
11.2.2  Vital Signs  .............................................................................................38  
11.2.3  Safety Laboratory Determinations  ........................................................38  
11.3  Stoppi[INVESTIGATOR_1869] .......................................................................................................38  
12.0  STATISTICAL ANALYSIS  ...........................................................................................38  
12.1  General Statistical Considerations  .........................................................................38  
12.2  Sample Size and Power  ..........................................................................................39  
12.2.1  Primary Objective: Rate of adverse events during and up to 4 weeks 
after radiation  ........................................................................................39  
12.2.2  Secondary Objectives  ............................................................................39  
12.3  Analysis Populations ..............................................................................................42  
12.4  Efficacy Analysis  ...................................................................................................42  
12.5  Safety Analysis  ......................................................................................................42  
Page 5 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
13.0  REGISTRATION GUIDELINES  ..................................................................................42  
14.0  DATA SUBMISSION SCHEDULE  ...............................................................................43  
15.0  ETHICAL AND REGULATORY CONSIDERATIONS  ............................................43  
15.1  Informed consent ...................................................................................................43  
15.2  Institutional Review  ...............................................................................................43  
15.3  Data and Safety Monitoring Plan  ...........................................................................43  
15.4  Adverse Events / Serious Adverse Events .............................................................44  
15.4.1  Adverse Events (AE) .............................................................................44  
15.4.2  Serious Adverse Event (SAE) ...............................................................45  
15.5  SAE Reporting Requirements ................................................................................46  
15.6  Protocol Amendments ............................................................................................47  
15.7  Protocol Deviations ................................................................................................47  
15.8  FDA Annual Reporting ..........................................................................................47  
15.9  Clinical Trials Data Bank .......................................................................................48  
16.0  REFERENCES  .................................................................................................................48  
ATTACHMENT 1:  RANO RESPONSE CRITERIA .............................................................51  
ATTACHMENT 2: COGSTATE INSTRUCTIONS  ...............................................................53  
ATTACHMENT 3: MDASI -BT .................................................................................................57  
 
                    
 
 
Page 6 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
LIST OF ABBREVIATIONS  
Abbreviation or Term1 Definition/Explanation  
AE Adverse event  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase  
β-HCG  Beta-human chorionic gonadotropin  
BID Twice daily  
BP Blood pressure  
BUN  Blood urea nitrogen  
CBC  Complete blood count  
CNS  Central nervous system  
CR Complete response  
CRF  Case report form  
CSF-1 Colony stimulating factor -1 [also known as macrophage stimulating factor (M -CSF)]  
CSF-1R Colony stimulating factor receptor (also known as Fms)  
CT Computed tomography  
CTCAE  Common Toxicity Criteria for Adverse Event s 
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
DLT  Dose Limiting Toxicity  
ECG  Electrocardiogram  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GFR  Glomerular filtration rate  
HIV Human immunodeficiency virus  
HR Heart rate  
hr Hour or hours  
IC50 Half maximal inhibitory concentration  
i.e. Id est (that is)  
IEC Independent ethics committee  
INR International normalized ratio  
Page 7 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
Abbreviation or Term1 Definition/Explanation  
IRB Institutional review board  
IU International unit  
IV Intravenous, intravenously  
LDH  Lactate dehydrogenase  
MedRA  Medical Dictionary for Drug Regulatory Activities  
MRI  Magnetic resonance imaging  
MTD  Maximum tolerated dose  
PD Pharmacodynamic(s)  
PFS Progression Free Survival  
PK Pharmacokinetic(s)  
PO Per os (administered by [CONTACT_1966])  
PR Partial response  
PT Prothrombin time  
PTT Partial thromboplastin time  
SAE  Serious adverse event  
T1/[ADDRESS_568647]  Upper limit of normal  
WBC  White blood cell  
1  All of these abbreviations may or may not be used in protocol .  
 
 
 
 
 
  
 
Page 8 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
 
PROTOCOL SIGNATURE  
  
I confirm that I have read this protocol, and I will conduct the study as outlined herein and according to the ethical principles stated in the latest version of the Declaration of Helsinki, the 
applicable ICH guidelines for good clinical practice, and the applicable laws and regulations of the federal government.  I will promptly submit the protocol to the IRB for review and approval. I understand that any modification made during the course of the study must first be approved by [CONTACT_154462].  
 I will provide copi[INVESTIGATOR_323724].  I will discuss this material with them to ensure that 
they are fully informed regarding the study treatment, the conduct of the study, and the obligations of confidentiality.  
 Note : This document is signed electronically through submission and approval by [CONTACT_9532] [INVESTIGATOR_447135] (ERICA) system.  
 
 
Page 9 of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
STUDY SUMMARY  
 
Title  A Phase 1 b/2 Study of Repeat rAdiation , Minocycline, and Bevacizumab 
in patients with recurrent gliOma (RAMBO)  
Protocol 
Number  IRB #  [ZIP_CODE]  
IND Exempt  
Phase  Phase 1b/2 
Study 
Objective(s)  The primary objective is the safety  of minocycline and bevacizumab during 
and 4 weeks after reirradiation.  The secondary objectives are, the response 
rate, PFS3, PFS6, and effects on quality of life and cognition from repeat radiation , minocycline and bevacizumab.  
Study Design  This will be an open label dose finding trial to assess the safety and efficacy of repeat radiation with bevacizumab  and minocycline in patients with 
recurrent glioma.  The maximum tolerated dose will be established  using 3 
patients per cohort and there will be an expansion cohort ( step 2) at the 
MTD .  A total of [ADDRESS_568648].  
Response rate and PFS will be based on MRI using RANO criteria.  Quality of life and cognition will be assessed before treatment and  1, 3, and 6 months 
after radiation . 
Study Duration  Patient recruitment period is approximately 30 months.   
Number of 
Patients/Sites  Enrollment will be [ADDRESS_568649].  Bevacizumab will be continued at 10mg/kg IV every 2 weeks.  Minocycline will be given twice a day starting at 100mg PO 
BID.  MRI, QOL, and cognitive tests will be obtained 1, 3 and 6 months 
after the end of radiation. 
Key Patient 
Selection Inclusion 
1. Male or female patients  ≥18 years old with a life expectancy of at 
Page 10  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
Criteria  least 8 wee ks 
2. Radiographically proven recurrent (≥ first relapse), intracranial 
glioma   
3. Previous treatment with external beam radiation  
4. Radiographic progression on current or prior bevacizumab  treatment  
by [CONTACT_28843]  
5. Women of child-bearing potential must have a negative pregnancy 
test within [ADDRESS_568650] been postmenopausal for ≥[ADDRESS_568651] dose. 
6. Karnofsky performance status of ≥50 
7. Adequate hematologic, hepatic, and renal function (absolute 
neutrophil count ≥1.0 x 10
9/L, Hgb >9 g/dL, platelet count ≥50 x 
109/L, AST/ALT ≤2.5x ULN, creatinine ≤1.5x ULN)  
8. Prothrombin time/international normalized ratio  (PT INR) < 1.4 for 
patients not on warfarin confirmed by [CONTACT_240599] 14 days prior to study registration  
9. Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must have no active bleeding or pathological condition that carries a high risk of bleeding, and must be on a stable dose of oral anticoagulant for 14 days or on a stable dose of low molecular weight heparin  for 14 days 
10. Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements 
 
Exclusion 
1. Use of an investigational drug within 14 days or within 5 half-lives of the investigational drug, whichever is shorter 
2. Less than 6  months since the end of previous radiation 
3. History of Grade 2 (CTCAE v4) or greater acute intracranial hemorrhage 
4. A concurrent active cancer that requires non -surgical therapy (e.g. 
chemotherapy, radiation, adjuvant therapy).  
5. Patients with serious illnesses, uncontrolled infection, medical conditions, or other medical history including abnormal laboratory results, which in the investigator’s opi[INVESTIGATOR_447136] a patient’s participation in the study, or with the interpretation of the results 
Page 11  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
6. Women of child -bearing potential who are pregnant or breast feeding  
7. Unstable angin a and/or congestive heart failure in the last [ADDRESS_568652] 6 months, [LOCATION_001] 
Heart Association grade II or higher congestive heart failure requiring hospi[INVESTIGATOR_21342] 12 months prior to registration, evidence of recent  (within 14 days of registration) myocardial infarction by [CONTACT_137884] 
(only required if clinically indicated), serious or inadequately controlled cardiac arrhythmia, significant vascular and peripheral 
vascular disease, evidence of bleeding diathesi s or coagulopathy 
8. History of stroke, cerebral vascular accident (CVA) or transient 
ischemic attack within [ADDRESS_568653]. 
Bevacizumab will be given 10mg/kg every 2 weeks. Minocycline will be 
given twice a day starting at 100mg PO BID with dose modification in each cohort based on adverse event rate in previous cohorts.   
Safety and 
Tolerability 
Assessments  Physical examinations, vital signs, and adverse events, will be used to assess safety and tolerability.  
Primary 
Endpoint  Adverse event rate  
Important 
Secondary 
Endpoints  PFS3, PFS6 , response rate, change in MDASI -BT at 1, 3, and 6 months, and 
change in COGSTATE at 1, 3, and 6 months 
Statistical 
Considerations Descriptive statistics will be used to estimate endpoint rates.   
 
Page 12  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
1.[ADDRESS_568654] frequent brain tumor, account ing for approximately 12% to 15% of all 
brain tumors ( CBTRUS ). The peak incidence occurs between the ages of 45 and 70 years.  
Patients with recurrent glioma are incurable.  Up front treatment options include surgery, 
radiation, and temozolomide chemotherapy  (Stupp et al.). According to the National Cancer 
Institute, p atients with brain tumors that are either infrequently curable or unresectable should be 
considered candidates for clinical trials that evaluate new drugs and biolo gical response 
modifiers following radiation therapy.  
Bevacizumab is FDA approved for glioblastoma that progre sses after temozolomide therapy  and 
is NCCN recommended for all gliomas after progression on temozolomide ( Brem et al. ).  There 
is no FDA approved therapy for gliomas following progression on bevacizumab.  The median 
progression free and overall survival after progression on bevacizumab is 1 and 3 months, respectively  (Kreisl et al. ).  Because of the risk of rebound edema and retrospective data 
suggesting a survival advantage , many neuro -oncologists continue bevacizumab after 
progression. ( D. A. Reardon) 
Although historically repeat radiation for gliomas was considered prohibitively toxic, modern radiation techniques allow for repeat radiation in many cases.  (Kim et al. ; Combs et al. ; 
Vordermark et al. ; Fogh et al. )  Most studies of re-irradiation have not reported response rates or 
progression free survival.  Moreover, most if not all patients in these series did not receive bevacizumab prior to re-irradiation, making them more favorable than current patients.  Coombs et al reported on re-irradiation of 172 patients with recurrent gliomas, 54 of whom had glioblastoma. (Combs et al. )  The median PFS of the glioblastoma patients was 5 months, with a 
PFS6 of 28%.  Fugh reported on 105 patients with high grade gliomas who received repeat radiation with hypofractionation, of whom 53 were glioblastoma.  Although 60% of patients had stable d isease at 3 months, only 10% had a partial response by [CONTACT_212567]. 
Two studies have directly addressed the question of reirradiation with concomitant bevacizumab. Niyazi treated thirty patients with repeat radiation , twenty of whom also received be vacizumab  
(Niyazi et al. ).  There was one grade 3 deep venous thrombosis and one grade 4 wound 
dehiscence. The response rate was not recorded.  The PFS6 was 72% for radiation with bevacizumab and 24% for radiation alone.  Gutin treated 25 bevacizumab- naïve patients with 
Page 13  of 58 
 

Pr ot o c ol n a me: Re pe at R a di ati o n, Mi n oc ycli ne a n d Be v aciz u m a b i n P atie nt s wit h Rec urre nt Gli o m a  
Versi o n D ate : 1 2/ 0 3/ 2 0 1 5  
Pri nci p al I n vesti g at o r:  A d a m C o he n, M D  
 
re peat ra diati o n a n d be vaciz u ma b ( G uti n et al. ).  T here w ere t hr ee gra de 3 t o xicities, a n 
i ntrat u m oral blee d, w o u n d de hisce nce, a n d b o w el perf or ati o n.   T he res p o nse rate w as 5 0 % a n d 
P F S 6 was a b o ut 6 4 %.  N eit her of t he pr e vi o us st u dies i ncl u de d patie nts w h o ha d pr o gress e d o n 
be vaciz u ma b, w h o mi g ht ha ve a differ e nt a d verse e ve nt rate or res p o ns e rat e. M ore o ver, n o 
st u dies ha ve d oc u me nte d q ualit y of life or c o g niti o n f oll o wi n g r e peat r a diati o n. 
Resista nce t o be vaciz u ma b a n d t o ra diati o n is  i nc o m pletel y u n derst o o d.  I n d ucti o n of alter nat e 
pr o m oters of a n gi o ge n esis, i ncrease d i n v asi o n via i n d ucti o n of matri x metall o pr otei nases a n d c- 
M E T, h y p o xia i n d uce d r ecr uit me nt of b o ne m arr o w- deri ve d cells, a n d c o o pti o n of n or mal 
vessels ha ve all bee n h y p ot hesize d t o pla y a r ol e i n be vaciz u ma b resista nce. ( Ber gers a n d 
Ha na ha n ; L u ci o -Eter o vi c et al. )  Ra di or esista nce has bee n h y p ot hesize d t o be d ue t o a 
c o m bi nati o n of G B M ste m cells, w hic h ma y be pr otecte d b y m T O R, s ur vi vi n, ga m ma secr eatase, 
H y p o xia- i n d uce d N F - K B si g nali n g, or C O X- 2 , E G F R - me diate d d o u bl e str a n d D N A r e pair, 
S O C S - ge ne l oss, a n d micr o glia i n d ucti o n. ( C ha kra varti et al. ; Lal et al. ; Jia n g et al. ; Ric h ; 
Z h o u et al. ; M urat et al. ; Hata n paa et al. ; Li n et al. ; A na n d har aj et al. ; H ellstr o m et al. ; 
Z h ua n g et al. ) A ntia n gi o ge ni c a ge nts, i ncl u di n g b e vaciz u ma b, ca n i ncrease t he eff ecti ve ness of 
ra diati o n i n vi v o.( Lee et al. ; Ge n g et al. ) 
 
Ge ne e x pressi o n st u dies ha ve i de ntifie d m ulti ple s u bt y pes of gli o blast o ma i ncl u di n g a 
mese nc h y mal ( M E S) s u bt y pe ass ociate d wit h i ncr ease d a n gi o ge nesis a n d p o or s ur vi val ( P hilli ps 
et al. , C ol ma n et al. ). Pr o m oter a nal ysis of t he M E S s u bt y p e a n d i n g li o blast o ma ste m cells 
( G S Cs) has i de ntifie d se veral tra ns cri pti o n fact ors i ncl u di n g S T A T 3, C E B P B, a n d T A Z 
ass ociate d wit h t he M E S s u bt y pe ( C arr o et al; B hat et al). Rece nt st u dies ha ve i de ntifie d 
acti vati o n of N F k B as a ke y si g nali n g f act or pr o m oti n g t he M E S s u bt y pe t hr o u g h u pr e g ulati o n of 
t he M E S tra nscri pti o n fact ors ( Vailla nt et al; B hat et al) i n G S Cs a n d h u ma n t u m ors. 
F urt her m ore, acti vati o n of N F k B i n G S Cs b y T N F treat me nt res ulte d i n a M E S s hift, i ncrease d 
i n vasi o n, a n d ra diati o n resista nce. Bl oc k a de of N F k B acti vati o n b y I k B- a w as s ufficie nt t o 
pre ve nt t hese T N F i n d uce d eff ects.  I n v esti gati o n of p ote ntial s o urce of N F κ B acti vati o n i n G B M 
s u g geste d a r ole of micr o glia. I n d ee d, a d diti o n of s u per nata nt fr o m acti vate d micr o glia w as 
s ufficie nt t o acti vate N F κ B a n d M E S tra nsiti o n i n G S Cs t hat c o ul d be bl oc ke d b y I κ B-  
( Vailla nt et al.) . T o test t he r ole of micr o glia a n d N F κ B acti vati o n o n treat me nt resista nce i n 
vi v o, treat me nt wit h mi n oc ycli ne, a n i n hi bit or of micr o glia acti vati o n, le d t o a re d ucti o n of t u m or 
gr a de a n d d o w n-r e g ulati o n of M E S mar ker s i n i ntracr a nial G S C x e n o graft m o dels  ( Vailla nt et 
al.) . Ta ke n t o get her, t hes e data i n dicate a n i m p ort a nt r ole f or micr o glia acti vati o n of N F κB i n t he 
i n d ucti o n a n d mai nt e na n ce of t he M E S p he n ot y pe a n d ra diati o n r esista nce i n G B M a n d G S Cs. 
T hese data als o s u g gest t hat bl oc ka de of N F κ B a n d/ or i n hi biti o n of micr o glia acti vati o n ma y be 
attracti ve t her a pe utic a p pr oac hes f or d o w nre g ulati n g M E S tra nsiti o n a n d o verc o mi n g treat me n t 
resista nce i n G B M.  
 
 
Mi n oc ycli ne is a tetrac ycli ne - deri vati ve t hat is F D A a p pr o ve d as a n a nti bi otic.  It als o h as a nti- 
i nfla m mat or y pr o perties t hat are n ot s hare d b y all me m bers of t he tetr ac ycli ne fa mil y.  
Mi n oc ycli ne h as p ote ntial as a n a nti- gli o ma  a g e nt a n d a s a r a diati o n se nsitizer f or gli o ma .  
Mi n oc ycli ne i n hi bits matri x metall o pr otei nase e x pressi o n b y micr o glia, t h us re d uci n g gli o ma 
i n vasi o n a n d e x pa nsi o n. ( Mar k o vic et al. ) Mi n o c ycli ne als o i n d uces gli o ma cell deat h via 
P a g e 1 4  of 5 8  
 
Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
autophagy and apoptosis. (Liu et al. )  Animals treated with local administration of minocycline to 
tumo r xenografts have improved survival.  ( Weingart et al. ) 
 
Minocycline also decreases inflammation following hypoxic or cytotoxic injury to the brain.( Nutile -McMenemy et al. ) As such, it is currently being studied for neurodegenerative 
disorders.  Microglia has  been implicated in resistance to radiation .  As described above, 
intracranial GSC xenograft studies in [CONTACT_447179]’s lab and labs of his collaborators have shown 
that minocycline reverse s resistance to radiation in these molecularly faithful models of GBM 
tumors.  Because of its lipophilicity, minocycline is 100% bioavailable and does penetrate the brain. Minocycline is established to penetrate the CNS  in humans and is the recommended 
antimicrobial for various meningoencephalitides (Tsai et al. ; Agustin et al. ; Fang et al. ) In one 
study, after a single 200mg dose of minocycline, the CSF to serum ratio in one subject is 0.54. (Carney et al. )  In another study of a single subject, after several days of treatment at 1 00mg 
twice a day, the CSF to serum ratio was 0.10- 0.2.  ( Macdonald et al. )  In dogs, the concentration 
of minocycline in the brain is between on- half and three times that in the serum. (Kelly and 
Kanegis ; Barza et al. ) In rats, after 5 -7 days of oral treatment, the brain concentration of 
minocycline is approximately equal to plasma concentrations.  ( Smith et al. )  In horses, after 2 
days of oral treatment, the CSF concentration of minocycline is approximately 50% of plasma concentration.  ( Schnabel et al. )   
 
Minocycline can inhibit TNF secretion and NF- κB act ivation at concentrations less than 5µM, 
which is the serum concentratiom achieved after a single dose of 200mg.  ( Bernardino et al. ; 
Huang et al. ) Microglia proliferatio n and activation may be suppressed at minocycline 
concentrations as low as 20 nM.  ( Tikka et al. ; Tikka et al. ) At the usual dose of 100mg twice a 
day, the serum concentration averages about 4µM after several days.  (Macdonald et al.)  Two 
people treated at 400mg per day had serum levels of 6-12 µM.  Therefore, although 100mg twice a day may be achieve high enough doses in the brain to induce a mesenchymal to proneural shift, higher doses may be necessary.   
 The long term tolerability  of minocycline has been studied in patients with ALS, in whom the 
mean long-term tolerated dose of minocycline was 387mg per day.  ( Gordon et al. )  Adverse 
effects were mainly gastrointestinal upset and nonsignificant increases in transaminases.  It is likely that glioblastoma patients  would have higher tolerance for these effects than ALS patients, 
and antiemetics and bowel motility agents used as supportive care for temozolomide may ameliorate the gastrointestinal effects.  Minocycline doses of 5mg/kg/day for [ADDRESS_568655] been well tolerated in animals without significant skin toxicity.  (Sotomayor et al. ; Teicher et al. )  This is not surprising because minocycline is considered much 
less phototoxic than other tetracyclines and does not share their release of ionized oxygen in response to UV light.  ( Hasan and Khan )  Daily intravenous doses of 10mg/kg/day for 3 days 
were tolerated b y stroke patients in the MINOS dose finding study ( Fagan et al. )   In a long- term 
study in people with Parkinson’s disease, 77% of people were able to take 200mg twice a day for 18 months without quitting.   Therefore, we propose to start at the usual antimicrobial dose of 100mg PO BID and increase up to a maximum dose of 800mg PO BID.  Because the long term 
Page 15  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
safety of minocycline is well established, we will limit the phase 1 component of this study to 
acute toxicity that occurs during or immediately after chemoradiation.  
 
Therefore, we hypothesize that addition of minocycline and bevacizumab to reirradiation for GBM after progression on bevaci zumab will incre ase efficacy without adding significant 
toxicity.  Because minocycline has not been tested with radiation in humans and other drugs in the same class (such as tetracycline) can have photosensitizing effects , we will first establish the 
safety of this combination and then extend the study to assess for evidence of efficacy.   As a single agent, the mean long- term tolerated dose of minocycline is 387mg per day.  ( Gordon et 
al.)  Adverse effects were mainly gastrointestinal upset and nonsignificant increases in 
transaminases.  Minocycline doses of 5mg/kg in combination with radiation have been well 
tolerated in ani mals.  (Sotomayor et al. ; Teicher et al. ) 
 
2.1 Bevacizumab  
2.1.1 Description  
 Bevacizumab is a recombinant humanized anti-VEGF monoclonal antibody, consisting of 93% human and 7% murine amino acid sequences. The agent is composed of human IgG framework and murine antigen- binding complementarity -determining regions.  
Bevaciz umab blocks the binding of vascular endothelial growth factor (VEGF) to its 
receptors resulting in inhibition of angiogenesis.  
 
2.1.1 Bevacizumab Safety  
Adverse Events >10%:  
 Cardiovascular: Hypertension (23% to 67%; grades 3/4: 5% to 18%), thromboembolic event (≤21%; grades 3/4: 15%; venous thrombus/embolus: 8%; grades 3/4: 5% to 7%; arterial thrombosis 6%; grades 3/4: 3%), hypotension (7% to 15%)  
 Central nervous system: Pai n (31% to 62%), headache (24% to 37%; grades 3/4: 2% to 
4%), dizziness (19% to 26%), fatigue (≤45%; grades 3/4: 4% to 19%), sensory neuropathy (grades 3/4: 1% to 17%; in combination with paclitaxel: 24%) 
 Dermatologic: Alopecia (6% to 32%), dry skin (7% to 20%), exfoliative dermatitis (3% 
to 19%), skin discoloration (2% to 16%) 
 Endocrine & metabolic: Hypokalemia (12% to 16%)  Gastrointestinal: Abdominal pain (50% to 61%; grades 3/4: 8%), vomiting (47% to 52%; grades 3/4: 6% to 11%), anorexia (35% to 43%), constipation (29% to 40%), diarrhea (grades 3/4: 1% to 34%), stomatitis (25% to 32%), gastrointestinal hemorrhage (19% to 24%), dyspepsia (17% to 24%), taste disorder (14% to 21%), flatulence (11% to 19%), weight loss (9% to 20%), nausea (grades 3/4: 4% to 12%)  
 Hematologic: Hemorrhage (≤40%; grades 3/4: 1% to 5%), leukopenia (grades 3/4: 
37%), neutropenia (grade 4: 6% to 27%)  
 Neuromuscular & skeletal: Weakness (57% to 74%), myalgia (8% to 19%), back pain (≤12%)  
 Ocular: Tearing increased (6% to 18%) 
Page 16  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 Renal: Proteinuria (4% to 36%; grades 3/4: ≤7%; median onset: 5.6 months; median 
time to resolution: 6.1 months)  
 Respi[INVESTIGATOR_696]: Upper respi[INVESTIGATOR_4416] (40% to 47%), epi[INVESTIGATOR_3940] (16% to 35%), 
dyspnea (25% to 26%), rhinitis 
 Miscellaneous: Infection (≤55%; serious: 9% to 14%; pneumonia, catheter, or wound 
infections) 
 
1% to 10%: 
 Cardiovascular: DVT (6% to 9%; grades 3/4: 9%), HF (grades 3/4: 1% to 4%), syncope (grades 3/4: 3%), intra -abdominal venous thrombosis (grades 3/4: 3%), cardio-
/cerebrovascular art erial thrombotic event (2% to 4%), left ventricular dysfunction 
(grades 3/4: 1%) 
 Central nervous system: Confusion (1% to 6%), abnormal gait (1% to 5%); CNS hemorrhage (1% to 5%; grades 3/4: 1%), reversible posterior leukoencephalopathy syndrome ([RPLS] ≤ 1%) 
 Dermatologic: Nail disorder (2% to 8%), skin ulcer (≤6%), rash desquamation (grades 
3/4: 3%), wound dehiscence (1% to 6%), acne (≤1%)  
 Endocrine & metabolic: Dehydration (grades 3/4: 3% to 10%), hyponatremia (grades 3/4: 4%)  
 Gastrointestinal: Xeros tomia (4% to 7%), colitis (1% to 6%), ileus (grades 3/4: 4% to 
5%), gingival bleeding (2% to 4%), fistula (1%), gastrointestinal perforation (≤4%), gastroesophageal reflux (≤2%), gingivitis (≤2%), mouth ulceration (≤2%), tooth abscess (≤2%), intra-abdominal abscess (1%), gastritis (≤1%), gingival pain (≤1%) 
 Genitourinary: Polyuria/urgency (3% to 6%), vaginal hemorrhage (4%)  Hematologic: Neutropenic fever/infection (5%; grades 3 and/or 4: 4% to 5%), thrombocytopenia (5%) 
 Hepatic: Bilirubinemia (1% to 6%)  
 Neuromuscular & skeletal: Bone pain (grades 3/4: 4%), neuropathy (other than sensory: 
grades 3/4: 1% to 5%) 
 Ocular: Blurred vision (≤2%)  Otic: Tinnitus (≤2%), deafness (≤1%)  Respi[INVESTIGATOR_696]: Voice alteration (5% to 9%), pneumonitis/pulmonary infiltrates (grades 3/4: 5%), hemoptysis (nonsquamous histology 2%), pulmonary embolism (≤1%) 
 Miscellaneous: Infusion reactions (<3%)  
<1% (Limited to important or life -threatening): Anaphylaxis, anastomotic ulceration, 
angina, bladder perforation, cerebral infarction; fistula (biliary, bladder, bronchopleural, duodenal, enterocutaneous, esophageal, gastrointestinal, rectal, renal, tracheo esophageal [TE] and vaginal); gastrointestinal ulcer, hemorrhagic stroke, 
hypersensitivity, hypertensive crises, hypertensive encephalopathy, intestinal necrosis, intestinal obstruction, mesenteric venous occlusion, microangiopathic hemolytic anemia (when used in combination with sunitinib), MI, nasal septum perforation, 
nephrotic syndrome, pancytopenia, polyserositis, pulmonary hemorrhage, pulmonary hypertension, renal failure, renal thrombotic microangiopathy, sepsis, subarachnoid hemorrhage, toxic anterior segment syndrome (TASS), transient ischemic attack, ureteral stricture wound healing complications 
Page 17  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
Reported from unlabeled use: Eye disorders: Endophthalmitis, hemorrhage 
(conjunctival, retinal or vitreous), intraocular inflammation (iritis, vitritis), intraocular 
pressure increased, ocular hyperemia, ocular pain/discomfort, retinal detachment, visual disturbance, vitreous floaters 
 
2.2 Minocycline  
2.2.1 Description  
Minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7 -
Bis(dimethylamino) 1,4,4a,5,5a,6,11,12a- octahydro -3,10,12,12a- tetrahydroxy -1,11-
dioxo-2-naphthacenecarboxamide monohydrochloride. 
Its structural formula is: 
 
C23H27N3O7•HCl M.W. 493.95 
 
2.2.2 Clinical Pharmacology 
Following a single dose of two minocycline hydrochloride 100 mg capsules 
administered to 18 normal fasting adult volunteers, maximum serum concentrations 
were attained in 1 to 4 hours (average 2.1 hours) and ranged from 2.1 to 5.1 mcg/mL 
(average 3.5 mcg/mL).The serum half-life in the normal volunteers ranged from 11.1 to 
22.1 hours (average 15.5 hours).  
When minocycline hydrochloride capsules were given concomitantly with a high- fat 
meal, which included dairy products, the extent of absorption of minocycline 
hydrochloride capsules was unchanged compared to dosing under fasting conditions. 
The mean Tmax was delayed by [CONTACT_447155], compared to 
dosing under fasting conditions. Minocycline hydrochloride capsules may be 
administered with or without food. 
In previous studies with other minocycline dosage forms, the minocycline serum half-
life ranged from [ADDRESS_568656] that 
of other tetracyclines.  
Page 18  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
2.2.3 Adverse Reactions  
Due to oral minocycline’s virtually complete absorption, side effects to the lower 
bowel, particularly diarrhea, have been infrequent. The following adverse reactions 
have been observed in patients receiving tetracyclines.  
Body as a whole: Fever, and discoloration of secretions. 
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, dyspepsia, stomatitis, glossitis, 
dysphagia, enamel hypoplasia, enterocolitis, pseudomembranous col itis, pancreatitis, 
inflammatory lesions (with monilial overgrowth) in the oral and anogenital regions. 
Instances of esophagitis and esophageal ulcerations have been reported in patients 
taking the tetracycline -class antibiotics in capsule and tablet form.  Most of these 
patients took the medication immediately before going to bed (See DOSAGE AND 
ADMINISTRATION).  
Genitourinary: Vulvovaginitis.  
Hepatic toxicity: Hyperbilirubinemia, hepatic cholestasis, increases in liver enzymes, 
fatal hepatic failure, and jaundice. Hepatitis, including autoimmune hepatitis, and liver 
failure have been reported (See PRECAUTIONS).  
Skin: Alopecia, erythema nodosum, hyperpi[INVESTIGATOR_447137], pruritus, toxic 
epi[INVESTIGATOR_194], and vasculitis. Maculopapular and erythematous rashes. 
Exfoliative dermatitis has been reported. Fixed drug eruptions have been reported. 
Lesions occurring on the glans penis have caused balanitis. Erythema multiforme and 
Stevens -Johnson syndrome have been reported. Photosensitivity is discussed above 
(See WARNINGS). Pi[INVESTIGATOR_447138]. 
Respi[INVESTIGATOR_696]: Cough, dyspnea, bronchospasm, exacerbation of asthma, and pneumonitis.  
Renal toxicity: Interstitial nephritis. Elevations in BUN have been reported and are 
apparently dose related (See WARNINGS). Reversible acute renal failure has been 
reported. 
Musculoskeletal: Arthralgia, arthritis, bone discoloration, myalgia, joint stiffness, and 
joint swelling.  
Hypersensitivity reactions: Urticaria, angioneurotic edema, polyarth ralgia, anaphylaxis/ 
anaphylactoid reaction (including shock and fatalities), anaphylactoid purpura, 
myocarditis, pericarditis, exacerbation of systemic lupus erythematosus and pulmonary 
infiltrates with eosinophilia have been reported. A transient lupus-like syndrome and 
serum sickness -like reactions also have been reported.  
Blood: Agranulocytosis, hemolytic anemia, thrombocytopenia, leukopenia, 
neutropenia, pancytopenia, and eosinophilia have been reported.  
Page 19  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
Central Nervous System: Convulsions, dizziness, hypesthesia, paresthesia, sedation, 
and vertigo. Bulging fontanels in infants and benign intracranial hypertension 
(pseudotumor cerebri) in adults have been reported (see PRECAUTIONS - General). 
Headache has also been reported.  
Other: Thyroid cancer has be en reported in the postmarketing setting in association 
with minocycline products. When minocycline therapy is given over prolonged periods, 
monitoring for signs of thyroid cancer should be considered. When given over 
prolonged periods, tetracyclines have been reported to produce brown-black 
microscopic discoloration of the thyroid gland. Cases of abnormal thyroid function 
have been reported. 
Tooth discoloration in children less than 8 years of age (see WARNINGS) and also, in 
adults has been reported.  
Oral cavity discoloration (including tongue, lip, and gum) has been reported.  
Tinnitus and decreased hearing have been reported in patients on minocycline 
hydrochloride. 
The following syndromes have been reported. In some cases involving these 
syndromes, death has been reported. As with other serious adverse reactions, if any of 
these syndromes are recognized, the drug should be discontinued immediately:  
Hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exfoliative 
dermatitis), eosinophilia, and one or more of the following: hepatitis, pneumonitis, 
nephritis, myocarditis, and pericarditis. Fever and lymphadenopathy may be present.  
Lupus- like syndrome consisting of positive antinuclear antibody; arthralgia, arthritis, 
joint stiffness, or joint swelling; and one or more of the following: fever, myalgia, 
hepatitis, rash, and vasculitis.  
Serum sickness -like syndrome consisting of fever; urticaria or rash; and arthralgia, 
arthritis, joint stiffness, or joint swelling. Eosinophilia may be prese nt. 
 
3.0 RATIONALE  
As described above, there is a strong rationale for the use of bevacizumab and minocycline with 
repeat irradiation.  However, no study has adequately documented the safety and efficacy of 
repeat radiation with bevacizumab and minocycline in people with recurrent glioma who 
progress on bevacizumab.   
Page 20  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
4.0 STUDY DESIGN  
4.1 Description  
This is an open -label, multi- agent  design .  Bevacizumab will be administered in accordance with 
the FDA -approved dose for gliomas, 10mg/kg IV every 2 weeks.  Bevacizumab will be 
continued every two weeks as long as tolerated .    One cycle of bevacizumab will be 28 days, 
with treatments on day1 and day 15.  Blood pressure, CBC, CMP, and urine protein level, either 
by [CONTACT_447156]/creatinine ratio will be checked at the beginning of each cycle.  
Radiation planning will be individualized by [CONTACT_447157].  The length and fractionation will be determined individually by [CONTACT_280545].   
Minocycline will be given by [CONTACT_326372] a day starting at about half of the monotherapy 
maximal tolerated dose, 100 mg PO BID. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.  During the combined radiation, 
minocycline, and bevacizumab treatment, patients will be seen weekly with a CBC, CMP, and adverse event monitoring. 
4.2 Dose Limiting Toxicity  
Dose level  Dose  
-1 75mg PO BID  
0 100mg PO BID  
1 200mg PO BID  
1A (in case of DLT at dose level 1)  150mg PO BID  
2 400mg PO BID  
 
The toxicities described below will be considered DLT’s if they are felt to be possibly, probably 
or definitely related to the minocycline.  Patients experiencing a DLT will have minocycline stopped until the toxicity resolves to grade [ADDRESS_568657] dose level if agreed by [CONTACT_102], the treating physician, and the PI. 
Page 21  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
Dose limiting toxicity will be determined in step 1 only during and 4 w eeks after radiation.  The 
initial cohort of 3 patients will receive dose level 0 (100mg PO BID).  If 2 or 3 patients 
experience a related grade 3 or higher toxicity or related intolerable grade 2 toxicity (particularly, 
bullous dermatosis, photosensitivit y, scalp pain not able to be controlled by [CONTACT_447158]) , other than anemia, cholesterol, lymphopenia, or weight gain, which will only be 
considered dose limiting if grade 5, within [ADDRESS_568658] dose at which 1 or 0 patients experience related grade 3 or higher toxicity will be declared the maximum tolerated dose (if dose level -1 or 0) or 
maximum achieved dose (if dose level 1 , 1A or 2) and will be used for step 2. 
Enrollment in the dose expansion portion (step 2) will not begin until adverse events have been reviewed by [CONTACT_447159]/maximum achieved dose has been approved by [CONTACT_90398] . 
4.[ADDRESS_568659] day of radiation until progression or intolerance.  Assessment of dose limiting toxicities  for stage 1 will end 4 weeks after the end of radiation. Assessmen t of 
adverse events will continue until the patient has been removed from study treatment. 
4.6 Duration of Study  
Approximately 1 patient is expected to enroll every 2 months, for a total of 6 per year.  Radiation treatment usually lasts 3 -4 weeks for each pati ent, so patients will be followed for dose limiting 
toxicities  for a total of 7 -8 weeks and for clinical and QOL measures for 6 months.  Total 
recruitment time for the study will be 3 years.  
Page 22  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
5.[ADDRESS_568660] (IRB)/independent ethics committee (IEC) -
approved informed consent form. The study begins with the signing and dating of the informed consent form. Patients must also meet the inclusion and exclusion criteria to be enrolled in the  
study.  
This eligibility checklist is used to determine patient eligibility and filed with signature [CONTACT_447177].  
  
Patient No. ______________________  Patient’s Initials: (L,F,M) _________________ 
 
5.1 Inclusion Criteria  
Yes/No  (Response of “no” = patient ineligible) 
 
_____ 5.1.1 Male or female patients ≥ [ADDRESS_568661] 8 
weeks  
 
_____ 5.1.2  Radiographically proven recurrent (≥ first relapse), intracranial glioma   
 
_____ 5.1.[ADDRESS_568662] been postmenopausal for ≥[ADDRESS_568663] dose. 
 
_____ 5.1.6  Karnofsky performance status of ≥50 
 
_____ 5.1.7  Adequate hematologic, hepatic, and renal function (absolute neutrophil 
count ≥1.0 x 10
9/L, Hgb >9 g/dL, platelet count ≥50 x 109/L, AST/ALT 
≤2.5x ULN, creatinine ≤1.5x ULN)  
Page 23  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
_____ 5.1.8  Proth rombin time/international normalized ratio (PT INR) < 1.4 for 
patients not on warfarin confirmed by [CONTACT_240599] 14 days prior to study 
registration.  
 
_____ 5.1.9  Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must 
have no active bleeding or pathological condition that carries a high risk of 
bleeding, and must be on a stable dose of oral anticoagulant for 14 days or on a stable dose of low molecular weight heparin for 14 days 
 
_____ 5.1.10  Willing and able to provide written informed consent prior to any study 
related procedures and to comply with all study requirements 
 
5.2 Exclusion Criteria  
Yes/No (Response of “yes” = patient ineligible) 
 
_____ 5.2.1  Use of an investigational drug within 14 days or within 5 half-lives of the 
investigational drug, whichever is shorter 
 
_____ 5.2.2  Less than 6 months since the end of previous radiation 
 
_____ 5.2.3 History of Grade 2 (CTCAE v4) or greater acute intracranial hemorrhage  
 
_____ 5.2.4  A concurrent active cancer that requires non -surgical therapy (e.g. 
chemotherapy, radiation, adjuvant therapy).  
 
_____ 5.2.5  Patients with serious illnesses, uncontrolled infection, medical conditions, 
or other medical history including abnormal laboratory results, which in the investigator’s opi[INVESTIGATOR_447136] a patient’s participation in the study, or with the interpretation of the results  
 
_____ 5.2.[ADDRESS_568664] feeding 
 
_____ 5.2.7  Unstable angina and/or congestive heart failure in the last [ADDRESS_568665] 6 months, [LOCATION_001] Heart Association grade II or higher congestive heart failure requiring hospi[INVESTIGATOR_21342] 12 months prior to registration, evidence of recent (within 14 da ys of registration) myocardial infarction by [CONTACT_137884] (only 
required if clinically indicated) serious or inadequately controlled cardiac 
arrhythmia, significant vascular and peripheral vascular disease, evidence of bleeding diathesis or coagulopathy. 
Page 24  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
_____ 5.2.8  History of stroke, cerebral vascular accident (CVA) or transient ischemic 
attack within [ADDRESS_568666] article are defined as screen failures.  For all screen fail ures, the investigator is to maintain a 
screening log that documents the screening number, patient initials, and reason(s) for screen failure.   
5.[ADDRESS_568667] article.  All previous treatments for glioma  should 
be recorded.  
Page 25  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
6.0 CONCOMITANT TREATMENT 
Concomitant treatment is permitted if the medication is not expected to interfere with the 
evaluation of safety or efficacy o f the study drug . During the study, if the use of any concomitant 
treatment becomes necessary ( e.g., for treatment of an adverse event), the treatment must be 
recorded on the CRF , including the reason for treatment, generic name [CONTACT_18467], dosage, route, 
and date of administration. 
7.0 TREATMENT PLAN  
Bevacizumab will be administered in accordance with the FDA -approved dose for gliomas, 
10mg/kg IV every 2 weeks.  Use screening or day 1 weight  throughout the study unless there is a 
10% weight change. Actual body weight will be used for all dose calculations of bevacizumab. 
Radiation will be given based on the judgment of the prescribing radiation oncologist.  
Minocycline will be given by [CONTACT_326372] a day starting at about half of the monotherapy maximal tolerated dose, 100 mg.  
7.1 Bevacizumab  
7.1.1 How Supplied , Stored, Packaged and Labeled  
Bevacizumab  is supplied as a clear to slightly opalescent, sterile liquid ready for 
parenteral administration. For Bevacizumab, each 100mg (25mg/mL – 4mL fill) and 
400 mg (25 mg/m L – 16 mL) glass vial contains bevacizumab with phosphate, 
trehalose, polysorbate 20, and Sterile Water for Injection, USP.   On receipt, bevacizumab should be stored in the refrigerator (2
o to 8 oC) and should 
remain refrigerated until just prior to use. Do not freeze. Do not shake. Shelf- life 
studies of bevacizumab are continuing. Investigators will be notified when lots have expi[INVESTIGATOR_5697]. The sterile single use vials contain no antibacterial preservatives; therefore, vials should be discarded eight hours after initial entry.  
 Bevacizumab will be supplied by [CONTACT_447160].  
7.1.2 Preparation and Administration 
Vials contain no preservative and are intended for single use only. The calculated dose should be placed in a 100 mL of 0.9% Sodium Chloride for Injection. Once diluted in 0.9% Sodium Chloride for Injection, the bevacizumab solution must be administered within 8 hours.   Bevacizumab is administered intravenously as a continuous infusion. The initial dose should be administered over a minimum of 90 minutes. If no adverse reactions occur after the initial dose, the second dose should be administered over a minimum of 60 minutes. If no adverse reactions occur after the second dose, all subsequent doses should be administered over a minimum of 30 minutes. If infusion- related adverse 
Page 26  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
reactions occur, all subsequent infusions should be administered over the shortest 
period that was well tolerated. To ensure complete delivery of bevacizumab, the IV infusion line must be flushed with 0.9% Sodium Chloride for Injection. Please note that this flush is not included in the infusion times. The following are two recommended methods for flushing the bevacizumab IV infusion line: When the bevacizumab  
infusion is complete, add an additional 50mL of 0.9% Sodium Chloride for Injection to the bevacizumab infusion bag. Continue the infusion until a volume equal to that of the volume contained in the tubing has been administered. Replace the empty bevacizumab infusion bag with a 50mL bag of 0.9% Sodium Chloride for Injection and infuse a volume equal to the volume contained in the tubing.  
7.1.3 Accountability and Compliance  
Doses and infusions will be documented in the patient’s medical record.  
 
7.2 Minocycline 
7.2.1 How Supplied , Stored, Packaged and Labeled  
Each minocycline hydrochloride capsule, USP for oral administration contains the 
equivalent of 50 mg, 75 mg or 100 mg of minocycline. In addition each capsule 
contains the following inactive ingredients: corn starch and magnesium stearate.  
The 50 mg, 75 mg and 100 mg capsule shells contain: gelatin and titanium dioxide.  
The 75 mg and 100 mg capsule shells also contain black iron oxide. 
The imprinting ink contains: black iron oxide, potassium hydroxide, propylene glycol, 
and shellac 
Minocycline Hydrochloride Capsules USP, 50 mg  are Pi[INVESTIGATOR_8745]/Pi[INVESTIGATOR_447139] ‘3’ hard gelatin 
capsule filled with yellow granular powder and imprinted with ‘C’ on Pi[INVESTIGATOR_447140] ‘76’ on Pi[INVESTIGATOR_447141]. 
Minocycline Hydrochloride Capsules USP, 75 mg are White/Grey size ‘3’ hard gelatin 
capsule filled wi th yellow granular powder and imprinted with ‘C’ on White cap and 
‘77’ on Grey body with black ink. 
Minocycline Hydrochloride Capsules USP, 100 mg are Maroon/Pi[INVESTIGATOR_447139] ‘2’ hard 
gelatin capsule filled with yellow granular powder and imprinted with ‘C’ on Maroon cap and ‘78’ on Pi[INVESTIGATOR_447141]. 
Minocycline should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° 
to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light, 
moisture and excessive heat. Dispense in a tight, light- resistant container as defined in 
the USP.  
Page 27  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
Minocycline will be supplied by [CONTACT_447161].  
 
7.2.2 Preparation and Administration 
Minocycline hydrochloride capsules may be taken with or without food. 
Ingesti on of adequate amounts of fluids along with capsule and tablet forms of drugs in 
the tetracycline -class is recommended to reduce the risk of esophageal irritation and 
ulceration. The capsules should be swallowed whole. 
 
 
7.2.3 Accountability and Compliance  
Administrations and doses will be noted in the patient’s medical record. 
 
8.0 TOXICITIES AND DOS E MODIFICATION  
This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 4.0 
for adverse event and serious adverse event reporting.  A copy of the CTCAE Version 4.0 can be 
downloaded:  
(http://safetyprofiler -ctep.nci.nih.gov/CTC/CTC.aspx ). 
 
8.1 Bevacizumab  
Reduction/interruption of dosing for adverse events may take place at any time.  Below are 
guidelines for dosage modification for bevacizumab –related toxicities as well as guidelines for 
their management.   
 
Table 1: Dose Modifications 
Event  CTCAE.v4 .0 Grade  Action To Be Taken  
Allergic reactions  
or 
Acute infusional  
reactions/ cytokine 
release syndrome  Grade 1-2 If infusion -related or allergic 
reactions occur, premedications 
should be given with the next dose and infusion time may not be 
reduced for the subsequent  
infusion.  
 
Page 28  of 58 
 

Pr ot o c ol n a me: Re pe at R a di ati o n, Mi n oc ycli ne a n d Be v aciz u m a b i n P atie nt s wit h Rec urre nt Gli o m a  
Versi o n D ate : 1 2/ 0 3/ 2 0 1 5  
Pri nci p al I n vesti g at o r:  A d a m C o he n, M D  
 
Gra de [ADDRESS_568668] o p pe d a n d n ot restarte d o n  
t he  sa me da y. At t he p h ysicia ns’ 
discreti o n, be vaciz u ma b ma y be 
per ma ne ntl y disc o nti n ue d or re -
i nstit ute d wit h pre me dicati o ns a n d at 
a rate of 9 0 + 1 5 mi n. If 
be v aciz u m a b is re -i nstit ute d, t he 
p atie nt s h o ul d be cl osel y 
m o nit ore d f or a d ur ati o n  
c o m p ar a ble t o or l o n ger t h a n t he 
d ur ati o n of t he pre vi o us re acti o ns . 
Gra de 4  Disc o nti n ue be vaciz u ma b  
Arteri al T hr o m b osis  
- Car diac isc he mia/  
i nfracti o n  
- C N S isc he mia ( TI A,  
C V A)  
- a n y peri p heral or  
visceral arterial  
isc he mia/t hr o m b osis  Gra de 2 ( if ne w or  
w orse ne d si nce  
be vaciz u ma b t hera p y)  Disc o nti n ue be vaciz u ma b  
Gra de 3 -4 
Ve n o us T hr o m b osis  Gra de 3  
O R  
as y m pt o matic gra de 4  � H ol d be vaciz u ma b treat me nt. If 
t he pla n ne d d urati o n of f ull -d ose 
a ntic oa g ulati o n is < 2 wee ks, 
be vaciz u ma b s h o ul d be hel d u ntil  
t he f ull - d ose a ntic oa g ulati o n p eri o d 
is o ver.  
� If t he pla n ne d d urati o n of f ull -
d ose a ntic oa g ulati o n is > 2 we e ks, 
be vaciz u ma b ma y be res u me d  
d uri n g t he peri o d of f ull -d ose 
a ntic oa g ulati o n I F all of t he criteria 
bel o w are met:  
- T he s u bj ect m ust ha ve a n i n -ra n ge 
I N R ( us uall y 2 -3) o n a sta ble d ose of 
warfari n or be o n a sta ble d ose of 
he pari n pri or t o restarti n g 
be vaciz u ma b  
- T he s u bj ect m ust n ot ha ve 
pat h ol o gical c o n diti o ns t hat carr y 
hi g h ris k of blee di n g (e g, t u m or 
i n v ol vi n g maj or vessels or ot her 
c o n diti o ns)  
- T he s u bj ect m ust n ot ha ve ha d 
he m orr ha gic e ve nts w hile o n st u d y  
� If t hr o m b oe m b oli w orse n/re c ur 
u p o n res u m pti o n of st u d y t her a p y, 
disc o nti n ue be vaciz u ma b  
Gra de 4 (s y m pt o matic)  Disc o nti n ue be vaciz u ma b  
H y perte nsi o n *  [ Treat wit h a nti h y perte nsi ve me dicati o n as nee de d. T he g oal of B P c o ntr ol 
s h o ul d be c o nsiste nt wit h ge neral me dical practice]  
Gra de 1  C o nsi der i ncrease d B P m o nit ori n g  
Gra de 2 -3 as y m pt o matic  B e gi n or c o nti n ue a nti -h y perte nsi ve 
t hera p y a n d c o nti n ue be vaciz u ma b  
P a g e 2 9  of 5 8  
 
Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
-Grade 2 -3 Symptomatic  
 • Hold bevacizumab  until symptoms 
resolve  and h ypertension is grade 2 
or less 
• Begin or continue anti -
hypertensive therapy  
Grade 4  Discontinue bevacizumab  
Congestive Heart Failure  Grade 3 or 4  Discontinue bevacizumab  
Proteinuria  UPC ratio < 3 500mg/g  Continue bevacizumab  
 UPC ratio > 3 500mg/g  Hold bevacizumab until UPC 
<3500mg/g  
 Grade 4 or nephrotic syndrome  Discontinue bevacizumab  
Hemorrhage (CNS or pulmonary)  Grade 2 -4 Discontinue bevacizumab  
Hemorrhage (non -CNS; non -
pulmonary)  Grade 3  • Patients receiving full -dose 
anticoagulation should  
discontinue bevacizumab  
• For patients not on full -dose 
anticoagulation, hold  
Bevacizumab until ALL of the 
following criteria are met:  
- the bleeding has resolved and Hb is 
stable  
- there is no bleeding diathesis that 
would increase the risk of therapy  
- there is no anatomic or pathologic 
condition that could increase the risk 
of hemorrhage recurrence.  
• Patients who experience recurrence 
of grade 3 hemorrhage should 
discontinue study therapy  
 Grade 4  Discontinue bevacizumab  
RPLS (reversible posterior 
leukoencephalopathy  
syndrome or PRES (posterior 
reversible  
encephalopathy syndrome)   • Hold bevacizumab in patients 
with symptoms/signs su ggestive of 
RPLS; subsequent management 
should include MRI scans and control of HTN  
• Discontinue bevacizumab upon 
diagnosis of RPLS  
Wound dehiscence requiring 
medical or surgical intervention   Discontinue bevacizumab  
GI perforation, GI leak or fistula   Discontinue bevacizumab  
Bowel obstruction  Grade 2 requiring medical 
intervention  Hold bevacizumab until complete 
resolution, with a minimum of 4 
weeks after surgery.  
Grade 3 -4 • Hold bevacizumab until complete  
resolution  
• If surgery is required, patient may 
restart bevacizumab after full recovery from surgery, and at 
investigator’s discretion  
Other unspecified  
bevacizumab -related AEs ( except Grade 3  Hold bevacizumab until symptoms 
resolve to < grade 1  
Page 30  of 58 
 

Pr ot o c ol n a me: Re pe at R a di ati o n, Mi n oc ycli ne a n d Be v aciz u m a b i n P atie nt s wit h Rec urre nt Gli o m a  
Versi o n D ate : 1 2/ 0 3/ 2 0 1 5  
Pri nci p al I n vesti g at o r:  A d a m C o he n, M D  
 
c o ntr olle d  
na usea/ v o miti n g).  Gra de 4  Disc o nti n ue be vaciz u ma b  
• U p o n c o ns ult ati o n wit h t he 
pri nci p al i n vesti g at or, res u m pti o n 
of be vaciz u ma b ma y be c o nsi dere d 
if a patie nt is be nefiti n g fr o m 
t hera p y a n d t he gra de 4 t o xicit y is 
tra nsie nt, has rec o vere d t o < gra de 1 
a n d u nli kel y t o rec ur wit h 
re treat me nt  
* C urre nt C T C A E defi niti o ns use d b y C T E P:  
 
� Gra de 1: as y m pt o matic, tra nsie nt ( < 2 4 h o urs) i ncrease b y > 2 0 m m H g ( diast olic) or t o > 1 5 0/ 1 0 0 if  
pre vi o usl y W N L; i nter ve nti o n n ot i n dicate d  
� Gra de 2: rec urre nt or persiste nt ( >  2 4 h o urs) or s y m pt o matic i ncrease b y > 2 0 m m H g ( di ast olic) or t o > 1 5 0/ 1 0 0 if 
pre vi o usl y W N L; m o n ot hera p y ma y be i n dicate d  
� Gra de 3: re q uiri n g m ore t ha n o ne dr u g or m ore i nte nsi ve t hera p y t ha n pre vi o usl y  
� Gra de 4: life t hreate ni n g (e g, h y perte nsi ve cri sis)   
 
 
D ose i nterr u pti o ns f or Gr a de 2 n o n- he m at ol o gic t o xicit y f or u p t o 2 w ee k s ca n be i m ple me nte d 
at t he discreti o n of t he tr eati n g p h ysici a n t o ma na ge i nt oler a ble or cli nicall y si g nifica nt t o xicit y . 
N o d ose re d u cti o n is re q uire d w he n r es u mi n g tr eat me nt.  
8. 2  Mi n oc ycli ne  
D ose le vel  D ose  
-1 7 5 m g P O BI D  
0 1 0 0 m g P O BI D  
1 2 0 0 m g P O BI D  
2 4 0 0 m g P O BI D  
 
D uri n g t h e e x pa nsi o n p hase (ste p 2) or aft er t he first p ost -ra diati o n m o nt h d uri n g ste p 1, i f a 
patie nt e x perie nces a n e w gra de [ADDRESS_568669] be i nterr u pte d u ntil rec o ver y t o < gra d e 1 a n d t he n r ei ntr o d uce d at o n e 
l o wer d ose le v el.   T he f oll o wi n g t o xicities will  re q uire h ol di n g t he mi n oc ycli ne o nl y if gr a de 3 or 
hi g her t o xicit y is e x perie nce d: a ne mia, c h olester ol.  T he f oll o wi n g t o xicities will n ot re q uire 
h ol di n g t he mi n oc ycli ne: l y m p h o pe nia, w ei g ht gai n.    If a patie nt re q uires a t o xicit y relate d d ose 
dela y of > [ADDRESS_568670] 
d ose le vel if a gr ee d b y t h e patie nt, t he treati n g p h ysicia n, a n d t he PI.  D ose re d ucti o ns ar e 
P a g e 3 1  of 5 8  
 
Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
allowed until 100 mg PO BID (dose level 0), after which the patient must be removed from the 
study.    
8.[ADDRESS_568671] day of radiation should be obtained if possible for patients who discontinue the 
study for reasons other than disease progression and are not started on another therapy for their recurrent glioma, in order to capture PFS3 data.  
Patients withdraw n from the study for reasons other than toxicity or disease progression (e.g. 
protocol violation or noncompliance) may be replaced at the discretion of the investigator.   To be 
considered evaluable, patients must experience a drug -related dose- limiting tox icity or receive at 
least 28 days of minocycline and 2 infusions of bevacizumab. During the dose-escalation portion of the study (step 1), unevaluable patients will be replaced.  Treatment  may be discontinued for 
an adverse event or at the discretion of the investigator. 
             
Page 32  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
9.0 STUDY CALENDAR  
 
STUDY DAY►  Screening 
(within 21 
days of 
registration) Radiation  
Treatment 
Period  D1 (+/ - 7 
days) of each 
monthly 
bevacizumab 
cycle  D15 (+/ - 7 
days) of each 
monthly 
bevacizumab 
cycle  28 (+/ -14) 
days after the 
end of 
radiation  84 (+/ -14) 
days after the 
end of 
radiation  182 (+/ -28) 
days after the 
end of 
radiation  
EVENT▼        
Informed 
Consent  X       
Medical History  X       
Height  X       
Weight  X  X  X X X 
Vital Signs X X5 X X X X X 
Physical Exam 1 X X5   X X X 
Chem, Hem  X X5 X  X X X 
UA/UPC    X     
PT/INR X       
Pregnancy Test 2 X       
Karnofsky 
Performance 
Status Assessment  X    X X X 
QOL by [CONTACT_447162] -
BT X    X X X 
COGSTATE  X    X X X 
MRI Brain Scan3 X    X X X 
Concomitant Medications  X    X X X 
Adverse Events 4  X5 X X X X X 
Minocycline Administration   X
6 X X X X X 
Radiation   X      
Bevacizumab infusions   X X X    
EXPLANATION OF SUPERSCRIPTS:  
1. Complete physical exam (including neurological exam) at Screening, and neurological exam plus symptom -directed 
physical exam subsequently.  
2. For women of child-bearing potential only; must be within [ADDRESS_568672] sequences 
will be obtained and research sequences may be obtained.   Additional MRperfusion/spectroscopy scans may also be 
obtained.  
4. Assessment of adverse events  (dose limiting toxicities)  for determination of MTD will end 4 w eeks after the end of 
radiation ; adverse events will continue to be monitored until all study treatment has been discontinued . 
5. During the combined radiation, minocycline and bevacizumab treatment, patients  will be seen weekly with a CBC, CMP, 
sympt om directed physical exam, neurological exam, vital signs and adverse event monitoring.  
6. Minocycline administration should be started the day prior to radiation; a window of 7 days prior is allowed.  
Page 33  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
10.[ADDRESS_568673] a Screening evaluation that includes the 
following: 
1. Sign and date an IRB-approved informed consent form before any study- specific 
screening procedures are performed   
2. Medical  history 
3. Height , weight , vital signs (sitting blood pressure, pulse rate, respi[INVESTIGATOR_697], and 
temperature) , and physical examination 
4. Clinical laboratory evaluation [CBC with differential, CMP , PT/INR, serum pregnancy 
test (women of child -bearing potential) ] 
5. Karnofsky p erformance status assessment  
6. MRI brain scan within 21 days of registration  
7. Recording of concomitant medications 
Patients who do not meet all inclusion and exclusion criteria will be noted as screen failures. 
10.2  Baseline Evaluation 
Between screening/consent and the first dose of radiation, QOL will be assessed by [CONTACT_224957] -
BT and cognition by [CONTACT_447163] 
10.3 Day 1 of subsequent cycles (± 7 Days) 
On D1 of each cycle, patients will undergo the following procedures: 
1. Weight, vital signs  
2. CBC, CMP, and UA (urine protein to creatinine ratio if protein present on UA) 
3. AE monitoring 
4. Bevacizumab infusion 
10.4 Day 15 of subsequent cycles (± 7 Days) 
On D15 of each cycle, patients will undergo the following procedures: 
1. Vital signs  
Page 34  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
2. Bevacizumab infusion 
3. AE monitoring 
10.5 Weekly duri ng radiation 
Once per week during radiation, patients will undergo the following procedures: 
 
1. Vital signs  
2. CBC  
3. CMP  
4. AE monitoring 
5. Symptom- directed physical examination  plus neurological exam 
 
10.[ADDRESS_568674] -radiation 
Twenty -eight (+/ -7) days after the end of radiation,  patients will return to the clinic and undergo 
the following procedures: 
1. Weight, vital signs , and symptom- directed physical examination  plus neurological exam  
2.  CBC  
3. CMP  
4. Karnofsky performance status assessment  
5. MRI brain scan  
6. Recording of c oncomitant medications  
7. AE monitoring 
8. MDASI -BT 
9. COGSTATE  
10.[ADDRESS_568675] -radiation 
84 (+/- 14) days after the end of radiation, subjects are expected to return to the clinic and 
undergo the following procedures: 
1. Weight, vital signs , and symptom- directed physical examination  plus neurological exam 
Page 35  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
2. CBC  
3. CMP  
4. Karnofsky performance status assessment  
5. Recording of c oncomitant medications  
6. MRI brain scan  
7. MDASI -BT 
8. COGSTATE  
9. AE monitoring 
10.[ADDRESS_568676] -radiation 
182(+/ -28) days after the end of radiation, subj ects are expected to return to the clinic and 
undergo the following procedures: 
1. Weight, vital signs , and symptom-directed plus neurological physical examination. 
2. CBC  
3. CMP  
4. Karnofsky performance status assessment  
5. Recording of c oncomitant medications  
6. MRI brain  scan  
7. MDASI -BT 
8. COGSTATE  
9. AE monitoring 
10.9 Continuously during trial  
Minocycline oral administration  (adverse event monitoring will continue until patient is removed 
from study treatment).  
 
11.0 CRITERIA FOR EVALUATION AND ENDPOINT  
11.1 Efficacy Evaluation 
Response rate and PFS will be based on MRI using RANO criteria (see attachment 1).   PFS will 
be based on all evaluable patients in step [ADDRESS_568677] measurable disease by [CONTACT_28843].  
Page 36  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
Cognitiv e function will be assessed using Cogstate software, which is also being used in an 
RTOG trial open for low grade gliomas at HCI.  Cogstate consists of [ADDRESS_568678] will not be required to complete the cognitive function evaluation.   
 
[IP_ADDRESS] One Card Learning Test (OCLT) (visuoperceptual learning and memory) 
Standard playing cards appear in the center of the computer’s screen one at a time, and the subject presses one mouse button if the card was presented previously and the other mouse button if it was not. Eighty-eight items are presented, in 8 trials of 11 cards. Learning and  
memory are operationally defined as the ability to discriminate between previously presented  
and novel (ie, distractors) information. Recognition paradigms are especially useful for assessing encoding and storage of newly learned information (Delis 2000).  The test takes about 3 minutes. 
 
[IP_ADDRESS] Detection Test (DET) (sensory registration, vigilance, and reaction time)  
A playing card appears in the center of the screen and turns face-up every [ADDRESS_568679] takes about 3 minutes. 
 
[IP_ADDRESS] Identification Test (IDN) (basic information processing/decision speed) 
A playing card appears in the center of the screen and tu rns face -up every 1 to 2 second; 
The subject pushes one mouse button if the card is red and the other mouse button if it is black. There are [ADDRESS_568680] takes about 8 minutes. 
 
[IP_ADDRESS] Groton Maze Learning Test (GMLT) (spatial learning and executive functioning, 
including working memory, error monitoring, and ability to integrate feedback to modify problem solving) Subjects must learn a hidden pathway within a grid of tiles. Each time they click on a tile  
(using the mouse), they receive correct/incorrect feedback to help guide them through the pathway. Subjects must apply a set of simple rules to minimize errors. There are [ADDRESS_568681] takes about 8 minutes.  The instructions for the tests are given in attachment  2.   
 MDASI -BT will be given as a written questionnaire; it is given in attachment 3.  
Page 37  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
11.[ADDRESS_568682] dose of radiation to assess the MTD .  If the patient continues 
on minocycline, AE’s will be assessed until discontinuation of treatment. 
11.2.1  Physical Examination 
Complete  and symptom- directed physical examinations will be performed by a licensed 
physic ian (or physician’s assistant or nurse practitioner). 
11.2.2  Vital Signs  
Vital signs (blood pressure, respi[INVESTIGATOR_697], pulse rate and temperature) will be 
obtained in the sitting position. Patients should be sitting for 3-5 minutes prior to obtaining vital signs . 
11.2.3  Safety Laboratory Determinations 
Laboratory evaluations will be performed as noted in the flow chart.  
11.3 Stoppi[INVESTIGATOR_447142] 4.2 for definition and evaluation of Dose Limiting Toxicities  and stoppi[INVESTIGATOR_004] .  
 
 
12.0 STATISTICAL ANALYSIS  
12.1 General Statistical Considerations 
This is a  Phase 1/2, single institution, open- label study with the primary objective to estimate the 
adverse event rate during reirradiation with concomitant bevacizumab  and minocycline.  
Important secondary objectives are to est imate the PFS3 , PFS6, response rate and cognitive 
effects  with this regimen.  
Since thi s is an open- label, single regimen  clinical trial, descriptive statistics will be employed to 
analyze the data. Summary statistics for continuous variables will include t he mean, standard 
deviation, median, and range (minimum/maximum). C ategorical variables will be presented as 
Page 38  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
frequency counts and percentages , and time -to-event variables will be summarized by [CONTACT_5263] -
Meier plots, medians and range. 
The data will be tabulated and analyzed with respect to patient enrollment and disposition, 
demographic and baseline characteristics, prior and concomitant medications,  efficacy , and 
safety measures .  
Data listings will be created to support eac h table and to present all data collected.  
For efficacy analyses, a 1 -sided alpha of 0.2 without adjustment for multiple comparisons will be 
used 
12.2 Sample Size and Power  
12.2.1  Primary Objective: Rate of adverse events during and up to 4 weeks after 
radiation 
[IP_ADDRESS] Data needed  
1. Adverse events at each cycle during radiation  
2. Adverse events at [ADDRESS_568683]-radiation 
will be recorded on the Case Report Forms. 
 
[IP_ADDRESS] Statistical analysis 
Adverse event rates will be categorized as non -severe (CTCAE grade 1 -2) or 
severe (CTCAE grade 3 -4).  The rate of non- severe and severe adverse events 
will be reported.  In step 1, 3 patients per cohort will be used to define the maximum tolerated dose/maximum achieved dose to carry forward into step 2.  All patients treated at the step 2 dose will be used in all analyses.  
 
Fifteen patients at the final dose will give 80% power to detect any adverse 
even t affecting at least 10.2% of patients.  Margins of error, with alpha = 0.05, 
for estimates of any event affecting more than 1 patient in the trial will be less than 27%.  
 
12.2.2  Secondary Objectives  
[IP_ADDRESS] PFS3  
[IP_ADDRESS].1 Data needed  
1. Size of target lesion on MRI at baseline  
Page 39  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
2. Size of target lesion on MRI 12 weeks after the end of radiation 
[IP_ADDRESS].2 Statistical analysis 
With bevacizumab continuation alone, the PFS3 would be expected to 
be <10%.  Indeed, the median overall survival after progression on bevacizumab is 3 months.   In prior studi es in the bevacizumab -
refractory population, treatments with PFS3 of 10-20% and PFS6 of 0-10% were considered not effective. ( Reardon et al. )  On the other hand, 
chemotherapy with PFS 3 of ~40% and PFS6 of 16% was considered 
worthy of further study.  (Reardon et al. ) Assuming a 10% 
dropout/unevaluable rate, fifteen patients will give us [ADDRESS_568684] the n ull hypothesis of 10% if the true PFS3 is 30%.  
[IP_ADDRESS] PFS6  
[IP_ADDRESS].1 Data needed  
1. Size of target lesion on MRI at baseline  
2. Size of target lesion on MRI 26 weeks after the end of radiation 
[IP_ADDRESS].2 Statistical analysis 
With bevacizumab continuation alone, the PFS6 would be expected to be <10%.  In prior studies in the bevacizumab-refractory population, treatments with PFS3 of 10 -20% and PFS6 of 0- 10% were considered 
not effective. ( Reardon et al. )  On the other hand, chemotherapy with 
PFS3 of ~40% and PFS6 of 16% was considered worthy of further study.  ( Reardon et al. ) Assuming a 10% dropout/unevaluable rate, 
fifteen patients will give us [ADDRESS_568685] the null 
hypothesis of 5% if the true PFS6 is 21%. 
[IP_ADDRESS] Response rate  
[IP_ADDRESS].1 Data needed  
1. Size of target lesion on MRI at baseline  
2. Size of target lesion on MRI 12 weeks after the end of radiation 
[IP_ADDRESS].2 Statistical analysis 
In Fugh et al, the response rate to radiation alone was 10%.  For drug studies in recurrent gliomas after bevacizumab, response rates over 10% 
Page 40  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
have been considered evidence of efficacy for proceeding to further 
trials.  Assuming a 10% dropout/unevaluable rate, fifteen patients will give us [ADDRESS_568686] the null hypothesis of 10% response if the true response rate is at least 30%.  
[IP_ADDRESS] Quality of life change over time 
[IP_ADDRESS].[ADDRESS_568687]- radiation  
[IP_ADDRESS].[ADDRESS_568688] 
deviation for each item, subscore, and total score at each time point. 
[IP_ADDRESS] Cognitive change over time 
[IP_ADDRESS].[ADDRESS_568689]- radiation  
[IP_ADDRESS].2 Statistical analysis 
The primary endpoint of cogni tive function  is measured by a battery of 
tests: the Detection Test (DET), the  Identification Test (IDN), the One 
Card Learning Test (OCLT), and the Groton Maze Learning Test 
(GMLT). The primary outcome measure of the DET and IDN tests is speed of performance using the mean of the log10 transformed response times for correct responses  (lower score = better performance). 
Accuracy of performance is the primary outcome measure for the OCLT, using the arcsine transformation of the square root of the proportion of correct responses across 8 rounds (higher score = better 
performance). Number of errors is the  primary outcome measure for 
GMLT.  Each of the battery’s tests will be  evaluated using the [ADDRESS_568690] with a 2 -sided significance level of 0.05 t o determine if  there is a 
clinically meaningful difference in the average change of NCF score from baseline to  the time of assessment.  
Page 41  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
12.[ADDRESS_568691] one dose of  minocycline . 
12.4 Efficacy Analysis 
Response to treatment  will be evaluated using the Response Assessment in Neuro- Oncology 
(RANO) criteria ( Wen 2010). The response criteria are summarized in Attachment [ADDRESS_568692] results (hem atology and clinical 
chemistry), weight, and vital signs .  
Adverse event terms recorded on the eCRFs will be mapped to preferred terms using the Medical 
Dictionary for Drug Regulatory Activities (MedDRA
®) version 10.1 or later. All AEs will be 
summarized a ccording to the system organ class and preferred term within the organ class. 
Adverse events will be tallied for overall frequency (number and percentage of subjects), worst reported severity, and relationship to study drug for each preferred term per subject.  Serious 
adverse events will be similarly summarized.  Listings of deaths, SAEs, and AEs leading to early 
termination of study treatment or premature withdrawal from study will also be provided . 
Laboratory values will be categorized according to their CTCAE (version 4) toxicity grade and tabulated by [CONTACT_192723]- study toxicity grade.  
13.[ADDRESS_568693] meet all of the eligibility requirements listed in Section 5 prior to 
registra tion.   
Page 42  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
 
Study related screening procedures can only begin once the patient has signed a consent form.   Patients must not begin protocol treatment prior to registration.  
 
Treatment should start within five working days after registration.  
 
To register eligible patients on study, complete a Clinical Trials Office Patient Registration Form 
and submit to: [EMAIL_6714].  
 
14.0 DATA SUBMISSION SCHEDULE  
The Case Report Forms (CRFs) are a set of electronic forms for each patient that provides a record of the data generated according to the protocol.   CRF’s should be created prior to the 
study being initiated and updated (if applicable) when amendments to t he protocol are IRB 
approved.  These forms will be completed on an on -going basis during the study.  D ata will be 
entered into the CRFs via OnCore (clinical research management system) by [CONTACT_447164], as indicated on the Delegation of Duties log. The medical 
records will be source of verification of the data.  During the study, the CRFs will be monitored 
for completeness, accuracy, legibility and attention to detail by a member of the Research Compliance Office.   The data will be reviewed no less than annually by [CONTACT_447165].   The Investigator will allow the Data and Safety Monitoring Committee 
or Research Compliance Office personnel access to the patient source documents, clinical suppli es dispensing and storage area, and study documentation for the above -mentioned 
purpose.  The Investigator further agrees to assist the site visitors in their activities.  
 
15.[ADDRESS_568694] of University of Utah. 
15.3  Data and Safety Monitoring Plan 
A Data and Safety Monitoring Committee (DSMC) is established at Huntsman Cancer Institute (HCI) and approved by [CONTACT_349128]-being of patients enrolled on Investigator Initiated Trials  that do not have an outside monitoring review.  Roles and responsibilities of the 
DSMC are set forth in the NCI approved plan.  The activ ities of this committee include  a 
quarterly  review of adverse events  including SAEs, important medical events, significant 
revisions or amendments to the protocol, and approval of cohort/dose escalations.  If the DSMC and/or the PI [INVESTIGATOR_447143], the study will be stopped and will not be resumed until the issues are resolved. The DSMC also reviews  and approves audit reports 
generated by [CONTACT_349129].   
Page 43  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
  
o This is a Phase  I study . For each phase I study using an agent of potential risk a member 
of the DSMC will be assigned as the primary medical monitor.  The primary medical 
monitor will be notified immediately of all SAEs within 24 hours of knowledge of the event. A formal report should be submitted to the primary medical monitor within 10 days. All serious adverse events (SAEs) occurring in patients treated at HCI or its 
affiliates will also be reviewed by [CONTACT_447166]. Approval from the primary 
medical monitor is requ ired for all dose escalations.  The full committee will also review 
all grade 3 or greater toxicities for patients on treatment.  
  
15.4 Adverse Events  / Serious Adverse Events  
This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events) 
Version 4.0 for AE and SAE reporting.  An electronic copy of the CTCAE Version 4.0 can be 
downloaded from: http://safetyprofiler -ctep.nci.nih.gov/CTC/CTC.aspx  
15.4.1  Adverse Events (AE)  
An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. For the purposes of this study, the terms toxicity and adverse event are used interchangeably. Medical conditions/diseases present before 
starting study drug are only considered adverse events if they worsen after starting study drug. Abnormal laboratory values or test results constitute adverse events only if they induce clinical signs or symptoms, are considered clinically significant, or require therapy.  
 
A patient’s AE can occur from the time the patient receives the first dose of 
minocycline  up to the last dose of study treatment.  SAEs will continue to be monitored 
and captured for a [ADDRESS_568695], or other assessments. As far as possible, each adverse event should be evaluated to determine: 
1. the severity grade based on CTCAE v.4 (grade 1-5) 
2. its relationship to the study drug(s) (definite, probable, possible, unlikely, not 
related)  For multi- drug regimens, relationship will be assessed for all treatments.  
3. its duration (start and end dates or if continuing at final exam)  
Page 44  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
4. action taken (no action taken; study drug dosage adjusted/temporarily interrupted; 
study drug permanently discontinued due to this adverse event; concomitant 
medication taken; non-drug therapy given; hospi[INVESTIGATOR_059]/prolonged 
hospi[INVESTIGATOR_059])  
5. whether it constitutes a n SAE  
 
All ad verse events will be treated appropriately. Such treatment may include changes in 
study drug treatment as listed in the dose modification section of this protocol ( see 
section 8 for guidance). Once an adverse event is detected, it should be followed until its resolution, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome.  Information about common side effects already known about the commercial  drug is 
described in the Drug Information (section 2) and the FDA -approved product labels. 
This information will be included in the patient informed consent and will be discussed with the patient during the study  as needed.  
 All adverse events will be immediately recorded in the patient research chart.  
15.4.2  Serious Adverse Event (SAE)  
Information about all serious adverse events will be collected and recorded. A serious adverse event is an undesirable sign, symptom or medical condition which: 
• is fatal or life -threatening  
• results in persistent or significant disability/incapacity  
• is medically significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above 
• causes congenital anomaly or birth defect  
• requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]: 
o routine treatment or monitoring of the studied indication, not associated with 
any deterioration in condition (procedures such as central line placements, 
paracentesis, pain control) 
o elective or pre- planned treatment for a pre -existing condition that is unrelated to 
the indication under study and has not worsened since the s tart of study drug  
o treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
o social reasons and respi[INVESTIGATOR_447144] ’s general condition 
 
Any death from any cause while a patient is receiving treatment on this protocol or up 
to [ADDRESS_568696] dose of protocol treatment, or any death which occurs more 
Page 45  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
than [ADDRESS_568697] be reported to the DSMC, the FDA, and the IRB according to the requirements  described below:  
 
DSMC Notifications:  
• Email or provide verbal notification of event within 24 hours of knowledge to 
[EMAIL_6715] . 
• Email completed MedWatch 3500A form within 10 days to [EMAIL_6715] . 
• An HCI Research Compliance Officer will process and submit the SAE 
notification/MedWatch form to the proper DSMC member as necessary for each individual study.  
• The RCO will summarize and present all reported SAEs according to the DSMP at 
the quarterly DSMC meeting.  
 
FDA Notifications: 
• Adverse events occurring during the course of a clinical study that meet the 
following criteria will be promptly reported to the FDA:  
• Serious 
• Unexpected  
• Definitely, Probably or Possibly Related to the investigational drug  
• Fatal or life -threatening events that meet the criteria above will be reported within [ADDRESS_568698] knowledge of the event by [CONTACT_093]; followed by [CONTACT_58691] a report as possible within 8 additional calendar da ys. 
• All other events that meet the criteria above will be reported within [ADDRESS_568699] knowledge of the event by [CONTACT_093]. 
• The CRC will complete a MedWatch 3500A form on the reportable SAE, gather other relevant supporting information and forward this to the RCO within [ADDRESS_568700] knowledge of the event (5 days for fatal or life- threatening events).  
• An RCO Compliance Officer will review the SAE information for completeness, 
accuracy and applicability to the regulatory reporting requirements.  
• The Compliance Officer will ensure the complete, accurate and timely reporting of the event to the FDA. 
Page 46  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
• If the investigator of the IIT holds an investigational new drug application (IND), 
the Regulatory Coordinator will submit the report as an amendment to the application. 
• For studies with an IND, all other adverse events and safety information not 
requiring expedited reporting that occur or are collected during the course of the 
study will be summarized and reported to the FDA through the IND Annual Report. 
 
• IRB Notification:Events meeting the the University of Utah IRB reporting 
requirements ( http://www.research.utah.edu/irb/ ) will be submitted through the 
IRB’s electronic reporting system within 10 working days. 
• The CRC will provide all necessary safety information to the Research Compliance 
Office for submission of the event.  
 
*Medwatch 3500A form can be found at  
https://www.accessdata.fda.gov/scripts/medwatch/medwatch -online.htm  
 
15.[ADDRESS_568701] prevent any immediate action from being 
taken by [CONTACT_447167].  
15.7 Protocol Deviations 
A protocol deviation (or violation) is any departure from the defined procedures and treatment 
plans as outlined in the protocol version submitted and previously approved by [CONTACT_1201]. Protocol 
deviations have the potential to place participants at risk and can also undermine the scientific 
integrity of the study thus jeopardizing the justification for the research.  Protocol deviations are 
unplanned and unintentional events.  
 
Because some protocol deviations pose no conceivable threat to participant safety or scientific 
integrity, reporting is left to the d iscretion of the PI [INVESTIGATOR_422977]. 
The IRB requires the prompt reporting  of protocol deviations which are: 
• Exceptions to eligibility criteria.  
• Intended to eliminate apparent immediate hazard to a research participant or  
• Harmfu l (caused harm to participants or others, or place them at increased risk of harm - 
including physical, psychological, economic, or social harm), or  
• Possible serious or continued noncompliance  
15.8 FDA Annual Reporting  
This study is IND exempt therefore there are no annual reporting requirements to the FDA.   
 
Page 47  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
15.9 Clinical Trials Data Bank  
The study will be registered on http://clinicaltrials.gov  and the NCI CTRP (Clinical Trials 
Reporting Program) by [CONTACT_154464].  
 
16.0 REFERENCES  
 
(2008). "A pi[INVESTIGATOR_447145]: 18-month 
results." Clin Neuropharmacol 31(3): 141-150. 
Agustin, E. T., V. Gill, et al. (1994). "Mycoplasma pneumoniae meningoencephalitis 
complicated by [CONTACT_447168]." Heart Lung  23(5): 436 -437. 
Anandharaj, A., S. Cinghu, et al. (2011). "Rapamycin- mediated mTOR inhibition attenuates 
survivin and sensitizes gliobla stoma cells to radiation therapy." Acta Biochim Biophys 
Sin (Shanghai) 43 (4): 292 -300. 
Barza, M., R. B. Brown, et al. (1975). "Relation between lipophilicity and pharmacological 
behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dog s." 
Antimicrob Agents Chemother 8(6): 713-720. 
Bergers, G. and D. Hanahan (2008). "Modes of resistance to anti- angiogenic therapy." Nat Rev 
Cancer  8(8): 592 -603. 
Bernardino, A. L., D. Kaushal, et al. (2009). "The antibiotics doxycycline and minocycline 
inhibit the inflammatory responses to the Lyme disease spi[INVESTIGATOR_447146]." 
J Infect Dis  199(9): 1379-1388. 
Brem, S. S., P. J. Bierman, et al. (2011). "Central nervous system cancers." J Natl Compr Canc 
Netw  9(4): 352-400. 
Carney, S., R. A. Butcher, et al. (1974). "Minocycline excretion and distribution in relation to 
renal function in man." Clin Exp Pharmacol Physiol 1(4): 299-308. 
CBTRUS.  
Chakravarti, A., G. G. Zhai, et al. (2004). "Survivin enhances radiation resistance in primary 
human gliobla stoma cells via caspase-independent mechanisms." Oncogene  23(45): 
7494-7506. 
Combs, S. E., C. Thilmann, et al. (2005). "Efficacy of fractionated stereotactic reirradiation in 
recurrent gliomas: long -term results in 172 patients treated in a single institution." J Clin 
Oncol 23(34): 8863-8869. 
D. A. Reardon, J. J. V., A. Desjardins, K. Peters, A. D. Coan, J. E. Herndon, H. S. Friedman; 
(2011). "Bevacizumab (BV) continuation following BV progression: Meta- analysis of 
five consecutive recurrent glioblastoma (G BM) trials." J Clin Oncol. 
Fagan, S. C., J. L. Waller, et al. (2010). "Minocycline to improve neurologic outcome in stroke 
(MINOS): a dose -finding study." Stroke 41(10): 2283-2287. 
Fang, C. T., W. F. Ferng, et al. (1997). "Life-threatening scrub typhus with meningoencephalitis 
and acute respi[INVESTIGATOR_1505]." J Formos Med Assoc 96(3): 213-216. 
Fogh, S. E., D. W. Andrews, et al. (2010). "Hypofractionated stereotactic radiation therapy: an 
effective therapy for recurrent high -grade gliomas." J Clin Oncol 28(18): 3048-3053. 
Geng, L., E. Donnelly, et al. (2001). "Inhibition of vascular endothelial growth factor receptor 
signaling leads to reversal of tumor resistance to radiotherapy." Cancer Res  61(6): 2413-
2419. 
Page 48  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
Gordon, P. H., D. H. Moore, et al. (2004). "Placebo-controlled phase I/II studies of minocycline 
in amyotrophic lateral sclerosis." Neurology 62(10): 1845-1847. 
Gutin, P. H., F. M. Iwamoto, et al. (2009). "Safety and efficacy of bevacizumab with 
hypofractionated stereotactic irradiation for recurrent malignant gliomas. " Int J Radiat 
Oncol Biol Phys 75 (1): 156 -163. 
Hasan, T. and A. U. Khan (1986). "Phototoxicity of the tetracyclines: photosensitized emission 
of singlet delta dioxygen." Proc Natl Acad Sci U S A  83(13): 4604-4606. 
Hatanpaa, K. J., S. Burma, et al. (2010). "Epi[INVESTIGATOR_447147]: signal 
transduction, neuropathology, imaging, and radioresistance." Neoplasia 12(9): 675-684. 
Hellstrom, N. A., O. R. Lindberg, et al. (2011). "Unique gene expression patterns indicate 
microglial contribution to  neural stem cell recovery following irradiation." Mol Cell 
Neurosci  46(4): 710 -719. 
Huang, W. C., Y. Qiao, et al. (2010). "Direct protection of cultured neurons from ischemia- like 
injury by [CONTACT_214608]." Anat Cell Biol 43(4): 325 -331. 
Jiang, Z., N. Pore, et al. (2007). "Phosphatase and tensin homologue deficiency in glioblastoma 
confers resistance to radiation and temozolomide that is reversed by [CONTACT_447169]." Cancer Res  67(9): 4467-4473. 
Kelly, R. G. and L. A. Kanegis (1967). "Metabolism and tissue distribution of radioisotopi[INVESTIGATOR_447148]." Toxicol Appl Pharmacol 11(1): 171-183. 
Kim, H. K., A. F. Thornton, et al. (1997). "Results of re- irradiation of primary intracranial 
neoplasms with three-dimensional conformal therapy ." Am J Clin Oncol 20(4): 358-363. 
Kreisl, T. N., L. Kim, et al. (2009). "Phase II trial of single-agent bevacizumab followed by 
[CONTACT_20562]." J Clin 
Oncol 27(5): 740-745. 
Lal, B., S. Xia, et al. (2005). "Targeting the c-Met pathway potentiates glioblastoma responses to 
gamma -radiation." Clin Cancer Res  11(12): 4479-4486. 
Lee, C. G., M. Heijn, et al. (2000). "Anti- Vascular endothelial growth factor treatment augments 
tumor radiation response under normoxic or hypoxic conditions." Cancer Res  60(19): 
5565-5570. 
Lin, J., X. M. Zhang, et al. (2010). "gamma- secretase inhibitor -I enhances radiosensitivity of 
glioblastoma cell lines by [CONTACT_447170]133+ tumor cells." Arch Med Res  41(7): 519-529. 
Liu, W. T., C. H. Lin, et al. (2011). "Minocycline inhibits the growth of glioma by [CONTACT_447171]." Autophagy 7(2): 166-175. 
Lucio -Eterovic, A. K., Y. Pi[INVESTIGATOR_6683], et al. (2009). "Mediators of glioblastoma resistance and invasion 
during antivascular endothel ial growth factor therapy." Clin Cancer Res  15(14): 4589-
4599. 
Macdonald, H., R. G. Kelly, et al. (1973). "Pharmacokinetic studies on minocycline in man." 
Clin Pharmacol Ther  14(5): 852-861. 
Markovic, D. S., K. Vinnakota, et al. (2011). "Minocycline reduce s glioma expansion and 
invasion by [CONTACT_447172]1 -MMP expression." Brain Behav Immun  25(4): 
624-628. 
Murat, A., E. Migliavacca, et al. (2008). "Stem cell- related "self -renewal" signature [CONTACT_447178][INVESTIGATOR_447149]." J Clin Oncol 26(18): 3015-3024. 
Niyazi, M., U. Ganswindt, et al. (2010). "Irradiation and Bevacizumab in High- Grade Glioma 
Retreatment Settings." Int J Radiat Oncol Biol Phys . 
Page 49  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
Nutile -McMenemy, N., A. Elfenbein, et al. (2007). "Minocycline decreases in vitro microglial 
motility, beta1 -integrin, and Kv1.3 channel expression." J Neurochem  103(5): 2035-
2046. 
Reardon, D. A., A. Desjardins, et al. (2011). "Phase II study of metronomic chemotherapy with 
bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy." J 
Neurooncol 103(2): 371 -379. 
Reardon, D. A., A. Desjardins, et al. (2011). "Phase 2 study of carboplatin, irinotecan, and 
bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy." 
Cancer  117(23): 5351-5358. 
Rich, J. N. (2007). "Cancer stem cells in radiation resistance." Cancer Res  67(19): 8980-8984. 
Schnabel, L. V., M. G. Papi[INVESTIGATOR_69936], et al. (2011). "Pharmacokinetics and distribution of minocy cline 
in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations." Equine Vet J. 
Smith, D. L., B. Woodman, et al. (2003). "Minocycline and doxycycline are not beneficial in a 
model of Huntington's dis ease." Ann Neurol 54(2): 186-196. 
Sotomayor, E. A., B. A. Teicher, et al. (1992). "Minocycline in combination with chemotherapy 
or radiation therapy in vitro and in vivo." Cancer Chemother Pharmacol  30(5): 377-384. 
Stupp, R., W. P. Mason, et al. (2005). "Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma." N Engl J Med  352(10): 987-996. 
Teicher, B. A., S. A. Holden, et al. (1995). "Potentiation of cytotoxic therapi[INVESTIGATOR_447150]- 470 and 
minocycline in mice bearing EMT -6 mammary carcinoma." Breast Cancer Res Treat  
36(2): 227-236. 
Tikka, T., B. L. Fiebich, et al. (2001). "Minocycline, a tetracycline derivative, is neuroprotective 
against excitotoxicity by [CONTACT_447173]." J Neurosci  
21(8): 2580-2588. 
Tikka, T. M., N. E. Vartiainen, et al. (2002). "Minocycline prevents neurotoxicity induced by 
[CONTACT_447174][INVESTIGATOR_447151]." Brain  125(Pt 4): 722-731. 
Tsai, Y. H., R. S. Hirth, et al. (1980). "A murine model for listerial meningitis and 
meningoencephalomyelitis: therapeutic evaluation of drugs in mice." Chemotherapy  
26(3): 196-206. 
Vordermark, D., O. Kolbl, et al. (2005). "Hypofractionated stereotactic re- irradiation: treatment 
option in recurrent malignant glioma." BMC Cancer  5: 55. 
Weingart, J. D., E. P. Sipos, et al. (1995). "The role of minocycline in the treatment of 
intracranial 9L glioma." J Neurosurg 82(4): 635 -640. 
Wen, P. Y., D. R. Macdonald, et al. (2010). "Updated response assessment criteria for high- grade 
gliomas: response assessment in neuro- oncology working group." J Clin Oncol 28(11): 
1963-1972. 
Zhou, H., R. Miki, et al. (2007). "Reciprocal regulation of SOCS 1 and SOCS3 enhances 
resistance to ionizing radiation in glioblastoma multiforme." Clin Cancer Res  13(8): 
2344-2353. 
Zhuang, W., B. Li, et al. (2011). "Induction of autophagy promotes differentiation of glioma-
initiating cells and their radiosensitivity." Int J Cancer  129(11): 2720-2731. 
 
Page 50  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
ATTACHMENT 1 :  RANO RESPONSE CRITERIA  
Patients will be assessed by [CONTACT_342786] (radiographic assessment in neurooncology) 
criteria. (Wen et al. ). The response will be determined as outlined in the RANO criteria below. 
Measurable Disease  
a. Bidimensionally contrast -enhancing lesions with clearly defined margins by [CONTACT_447175], with two perpendicular diameters of at least [ADDRESS_568702] or surgical cavity represents a particularly difficult 
challenge. In general, such lesions should be considered nonmeasurable unless there is a 
nodular component measuring ≥ 10 mm in diameter. The cystic or surgical cavity should not be measured in determining response.  
Complete Response (requires all of the following): 
a. Complete disappearance of all enhancing measurable and non -measurable disease 
sustained  for at least [ADDRESS_568703] be on no steroids. 
e. Stable or improved non-enhancing (T2/FLAIR) lesions. 
f. Stable or improved clinically.  
Note: Patients with non-measurable disease cannot have a complete response. The best response 
possible is stable disease. 
Partial Response  (requires all of the following): 
a. Greater than or equal to 50% decrease compared to baseline in t he sum of products of 
perpendicular diameters (bi- dimensional measurements) of all measurable enhancing 
lesions sustained for at least [ADDRESS_568704] be assessed using the same techniques as  
baseline.  
Page 51  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
e. The steroid dose at the time of the scan evaluation should be no greater than the dose at 
time of baseline scan.  
f. Stable or improved non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared to baseline scan.  
g. Stable or improved clinically.  
Note: Patients with non-measurable disease cannot have a partial response. The best response possible is stable disease.  
Stable Disease (requires all of the following): 
a. Does not qualify for CR, PR, or progression. 
b. The designation of stable disease requires a minimum of 4-week duration. 
c. All measurable and non- measurable sites must be assessed using the same techniques as  
baseline.  
d. Stable non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared to baseline scan. In the event that the corticosteroid dose has been increased, the last scan considered to show stable disease will be the scan obtained when the corticosteroid  dose was equivalent to the baseline dose. 
e. Stable clinically.  
Progressive Disease (defined by [CONTACT_39132]): 
a. >25% increase in sum of the products of perpendicular diameters (bi-dimensional measurements) of enhancing lesions (over baseline if no decrease) on stable or increasing 
doses of corticosteroids. and/or 
b. Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared to baseline scan or best response foll owing initiation of therapy, 
not due to co-morbid events (radiation therapy, demyelination, ischemic injury, infection, seizures, postoperative changes, or other treatment effects). 
c. Any new lesion.  
d. Clear clinical deterioration not attributable to other cau ses apart from the tumor (e.g.,  
seizures, medication side effects, complications of therapy, cerebrovascular events, infection, etc.). The definition of clinical deterioration is left to the discretion of the treating physician,  but it is recommended that a decrease in 20% of KPS or from any 
baseline to 50% or less be considered, unless attributable to comorbid events. 
e. Failure to return for evaluation due to death or deteriorating condition. 
Assessment of Response  (Efficacy)  
Timing of the Evaluation of Response: Assessment of response will begin with the previous MRI . All scans are to be compared to the smallest measurement scan to date.  
Page 52  of 58 
 

Pr ot o c ol n a me: Re pe at R a di ati o n, Mi n oc ycli ne a n d Be v aciz u m a b i n P atie nt s wit h Rec urre nt Gli o m a  
Versi o n D ate : 1 2/ 0 3/ 2 0 1 5  
Pri nci p al I n vesti g at o r:  A d a m C o he n, M D  
 
 
A T T A C H M E N T 2: C O G S T A T E I N S T R U C TI O N S  
T E S T I N S T R U C TI O N S A N D A D MI NI S T R A TI O N P R O C E D U R E S  
A d diti o n al c o m me nts:  
1. T he c o m p uter use d f or t he c o g niti ve tests m ust be l ocate d i n a q ui et area relati vel y fr ee of 
distracti o ns a n d wit h reas o na ble li g hti n g, c o mf orta ble seati n g, a n d a ta bl e of s ufficie nt size f or 
t he c o m p uter. N o f a mil y me m bers or fri e n ds of t h e patie nt, or site c ollea g u es, ma y b e pr ese nt 
d uri n g testi n g, e v e n if t he y re mai n q uiet or sit i n t he bac k of t h e r o o m. 
2. Testi n g m ust be c o m pl ete d i n [ADDRESS_568705] be f oll o we d ver bati m (test 
i nstr ucti o n scri pts  f or eac h of t he 4 tests are pr o vi de d i n t he ne ur oc o g niti ve t ests ma n ual) wit h 
e ver y patie nt at e ver y st u d y visit.  
3. Tests are a d mi nistere d i n t he f oll o wi n g or d er t o e ver y patie nt:  
C o g St ate tests i nstr ucti o ns scri pt  
�I m p ort a nt 
T ur n t he c o m p uter s cree n s o t hat it faces t he s u bj ect. E ns ure t hat t he s cree n is p ositi o ne d s o t hat 
it is directl y i n  fr o nt of t h e s u bject ( n ot a n gle d t o t he si de) a n d at a c o mf orta ble dista nce fr o m t he 
s u bject. A dj ust t he scree n pi[INVESTIGATOR_447152] h if necessar y.  
 
Detecti o n Test ( D E T)  
Bef ore t he D etecti o n T est be gi ns, a s cree n a p pears t ha t all o ws t he s u bject t o practice e nteri n g 
“ yes” a n d “ n o” res p o nses via t he m o use. T he left m o use b utt o n is al wa ys “ n o” a n d t he ri g ht 
m o use b utt o n is al wa ys “ yes, ” re gar dless of t h e ha n d use d. E ns ure t hat t he s u bject u n dersta n ds 
b y pr actici n g clic ki n g t he p r o per b utt o ns se veral ti mes. D o n ot per mit t he s u bject t o use t he 
ke y b o ar d t o e nter res p o nses. 
Click E nter t o be gi n t he Detecti o n test.  
T he i nstr ucti o ns a p pear o n t he scree n. T he s u bject s h o ul d re a d t he m sile ntly as y o u re a d t he m 
al o u d. 
S ay, H as t he c ar d t ur ne d over ? Y o u are n o w g oi n g t o d o a pr actice. Y o u will o nly nee d t o use 
t he “ Y es ”  b utt o n f or t his t as k. I n t his t as k, a pl ayi n g c ar d will a p pe ar i n t he ce nter of t he 
scree n. Press t he “ Y es ”  b utt o n w he n t he c ar d t ur ns f ace - u p as f ast as y o u c a n. If y o u m a ke a 
mist a ke y o u will he ar a n err or s o u n d. T his m e a ns y o u h ave res p o n de d t o o s o o n. Try t o m a ke 
y o ur res p o nse as acc ur ate a n d f ast as p ossi ble after a c ar d t ur ns f ace- u p. Are y o u re a dy t o 
st art ?  
Click E nter t o be gi n t he practice ite ms. Re mi n d t he s u bject t o press t he “ Yes” b utt o n as s o o n as 
t he car d t ur ns 
face - u p. 
If t he s u bject a p p ears c o nf use d or r es p o n ds i nc orr ectl y, r e vie w t he test r e q uire me nts, i ncl u di n g 
use of t he ri g ht m o use b utt o n (t he “ Yes” b utt o n) f or res p o nses. E ns ur e t he s u bject u n dersta n ds 
t hat  i n t his test, all car ds s h o w n  are t he s a me J o ker car d. T h er e is n o nee d f or t he s u bject t o 
e x a mi ne details of t he car d cl osel y.  
W he n t he practice ite ms are c o m plet e, t he i nstr ucti o ns f or t he sc or e d or “real” p orti o n of t he test 
a p pear.  
S ay, H as t he c ar d t ur ne d over ? Y o u are n o w g oi n g t o d o t he re al test. Are y o u re a dy t o st art ? 
Click E nter t o be gi n t he sc ore d ite ms. 
P a g e 5 3  of 5 8  
 
Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
When presentation of items is complete, the Detection test ends and the Identification Test 
begins automatically.  
Identification Test (IDN)  
The instructions appear on the screen. The subject should read them silently as you read them 
aloud. Say, Is the card red? You are now going to do a practice. You will need to use both the “Yes” 
and “No” buttons for this task. In this task, a playing card wi ll appear in the center of the 
screen. As soon as it turns face-up you must decide: is the color of the card red? If it is red, 
press the “Yes” button. If it is not red, press the “No” button. If you make a mistake you will hear an error sound. Try to make your responses as accurate and fast as possible after a card turns face -up. Are you ready to start? 
Click Enter to begin the practice items. Remind the subject to press the “Yes” or “No” buttons as 
quickly and accurately as possible.  
If the subject appears confused or responds incorrectly, review the test requirements, including 
use of the left and  right mouse button (left button = “No” and right button = “Yes” for responses. 
Ensure the subject understands that in this test, all cards shown are the same Joker card, the only difference being color (red or black). There is no  need for the subject to examine details of the 
card closely.  
When the practice items are complete, the instructions for the scored or “real” portion of the test appear.  
Say, Is the  card red? You are now going to do the real test. Are you ready to start? 
Click Enter to begin the scored items. 
When presentation of items is complete, the Identification test ends and the One Card Learning Test begins automatically.  
One Card Learning Tes t (OCLT) 
The instructions appear on the screen. The subject should read them silently as you read them aloud. Say, Have you seen this card before in this task? You are now going to do a practice. You will 
need to use both the “Yes” and “No” buttons for this task. 
In this task, a playing card will appear face- down in the center of the screen and then turn 
face-up. As soon as a card turns face-up decide if you have seen it before in this task. Only a few of the face -up cards will repeat during the task. If yo u have seen the card before in this 
task, press the “Yes” button. If you have not seen the card before in this task, press the “No” button. If you make a mistake you will hear an error sound. Try to make your responses as accurate and fast as possible afte r the card turns face-up. 
Click Enter to begin the practice items.  
Ensure that the subject understands that now the stimuli are standard playing cards (no jokers, no tricks such as  slightly altered cards) and when deciding whether the card in view was shown 
before, color , number , and suit  must all be considered before responding. If the subject appears 
confused or responds incorrectly, review the test requirements, including use of the left and right mouse button (left button = “No” and right button = “Yes” for responses. When the practice items are complete, the instructions for the scored or “real” portion of the test appear.  
Say, Have you seen this card before in this task? Cards seen in the practice are not used again. 
You are now going to do the real test. 
Click Enter to begin the scored items. 
Page 54  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
If the subject appears confused, offer a single prompt. Say, Have you seen this card before in 
this task?  
When presentation of items is complete, OCLT ends and the Groton Maze Learning Test begins 
automatically.  
Groton Maze Learning Test (GMLT)  
Test administrators should expect to provide active assistance to subjects during the practice portions of this test, as it is somewhat complex. In  brief, subjects must find a hidden pathway in 
a grid of tiles. The practice portion involves a small grid, presented three times, and each time the subject must try to find the same hidden pathway. The scored portion involves a larger grid, presented five times, and each time the subject must try to find the same hidden pathway within the larger grid. Say, Find the hidden pathway. This is a practice to help you learn the rules of this maze. To 
begin, you must tap the top left blue tile, and then find the h idden pathway by [CONTACT_53737][INVESTIGATOR_447153] a time until you get to the tile in the lower right corner. The first time you try to find the 
pathway, you need to guess each step. A green tick means you were correct, but a red cross means the move was wrong. After a wrong move, you need to go back to the last correct tile, and then try a move in a different direction. The rules of  this task are: 
1. Only move to adjacent tiles (up, down, left, or right). 2. Do not move diagonally. 3. Do not move backwards along the pathway. 4. Do not tap twice on the same tile. Tap as quickly and accurately as you can. 
Click Enter to begin the practice maze.  
If the subject appears confused or responds incorrectly, review the four rules, including, if 
needed, that the blue tile is  the starting point and that after a red cross, go back to the last correct 
tile (green tick), click it, and try a  move in a different direction. 
When the target is reached, a new grid appears (the pathway is the same, however).  
Say, You must now find the same hidden pathway. To begin, tap the top left blue tile, and then 
tap on the hidden pathway one tile at a time until you get to the target tile. The rules are the same as before. Tap as quickly and accurately as you can. 
If the subject appears confused o r responds incorrectly, review the four rules, including, if 
needed, that the blue tile is the starting point and that after a red cross, go back to the last correct 
tile (green tick), click it, and try a  move in a different direction. When the target is r eached, a 
new grid appears (the pathway is the same, however).  
This process occurs for a total of three practice maze trials, after which the instructions appear once again. If the subject appears to be rushing and moving along the pathway so fast that gri dlines are being 
clicked (in other words, insufficient care or time is taken to position the mouse pointer within a tile before clicking), remind the subject not to rush and to work carefully. If grout lines are clicked, the computer doesn’t know which til e is selected and so will score the click (move) as an 
error.  
When the instructions screen appears, say, Find the hidden pathway. You are now going to do 
the real test.  To begin, you must tap the top left blue tile, and then find the hidden pathway by 
[CONTACT_53737][INVESTIGATOR_447154] a time until you get to the tile in the lower right corner. The first time 
you try to find the pathway, you need to guess each step. A green tick means you were correct, 
Page 55  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
but a red cross means the move was wrong. After a wrong move, you need to go back to the 
last correct tile, and then try a move in a different direction. The rules of this task are:  
1. Only move to adjacent tiles (up, down, left, or right). 2. Do not move diagonally. 3. Do not move backwards along the pathway. 4. Do not tap twice on the same tile.  
Tap as quickly and accurately as you can. 
Click Enter to begin the maze. Do not review task rules during the scored portions of the test. If, 
during the real test, subjects ask you to review the instructions because they forgot them or don’t 
know what to do, or ask you to clarify something, say, “ The rules won’t let me help you.” 
Encourage subjects to do their best. Encourage them to guess if they aren’t sure of the correct 
next move. When the target is reached, a new grid appears (the pathway is the same, however). This process occurs for a  total of five scored maze trials.  
Say, You must now find the same hidden pathway. To begin, tap the top left blue tile, and then 
tap on the hidden pathway one tile at a time until you get to t he target tile. The rules are the 
same as before. Tap as quickly and accurately as you can. 
Click Enter to begin. 
When GMLT is finished, the subject receives a cheer.  
The CogState tests are complete.  
© 2009 CogState Limited. (The above instructions script was edited slightly for clarity.)  
  
Page 56  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
ATTACHMENT 3: MDASI -BT 
 
 
 
Page 57  of 58 
 

Protocol name: [CONTACT_447176], Minocycline and Bevacizumab in Patient s with Recurrent Glioma  
Version Date: 12/03/2015  
Principal Investigator:  [INVESTIGATOR_447134], MD  
 
  
 
Page 58  of 58 
 
